gyrA Family assigned · medium auto-curated

H37Rv Rv0006 · MTBC0 mtbc0_000006 · 838 aa · 7302–9818 MTBC0 (+) · RefSeq NP_214520.1

Genomic neighbourhood (genome browser)

Open in full genome browser →

This gene (outlined) in its genomic context; arrows are neighbouring genes coloured by verdict. Click any gene to navigate. Pan and zoom in the full browser.

Annotation: from legacy to revised

Legacy (H37Rv / Mycobrowser)DNA gyrase subunit A
MTBC0 PGAP re-annotationDNA topoisomerase (ATP-hydrolyzing) subunit A
Revised (this work)DNA topoisomerase (ATP-hydrolyzing) subunit A. Pfam: DNA_topoisoIV (PF00521.27), DNA_gyraseA_C (PF03989.19).
Functional category (TubercuList)information pathways

Auto-curated: this verdict and function were generated by rules from PGAP + Pfam + Foldseek and have not been hand-reviewed.

In the literature (TB corpus sweep) 682 publications

682 TB publications mention this gene. 682 publications discuss this gene. Queried separately, 573 records carry a M. tuberculosis context and 108 a non-TB mycobacterial context (species named in the 40-record verified sample: M. leprae (24), M. abscessus (12), M. smegmatis (5), M. marinum (1)). The three counts come from three distinct PubMed queries (each with its own context filter), so they neither partition the total nor need to add up to it.

5 of 682: the most recently indexed records of the curated sweep at its date, not necessarily the most recent papers on this gene — the exhaustive list below is later and broader and may hold newer ones.
PublicationDate
Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis. doi:10.1371/journal.pone.0352863 2026
Rapid Detection of Resistance Mutations in Multidrug-Resistant Tuberculosis With GenoType MTBDRsl Assay. doi:10.1155/pm/6993694 2026
Assessing Corynebacterium glutamicum as a surrogate of Mycobacterium tuberculosis for DNA gyrase inhibitor design. doi:10.64898/2026.06.24.734172 2026
Application of multiplex PCR-based nanopore sequencing for rapid detection and surveillance of antimicrobial-resistant Mycoplasma bovis in Japanese dairy cattle. doi:10.1128/spectrum.01242-26 2026
Gemifloxacin resistance in Mycobacterium tuberculosis without QRDR mutations in gyrA or gyrB: evidence for non-canonical resistance mechanisms. doi:10.1128/spectrum.03710-25 2026
684 records returned by the alias sweep (a separate sweep from the 682 above; both are shown, neither is exhaustive)

Searched as: Rv0006, gyrA, Mb0006, ML0006, MMAR_0006, MSMEG_0006, MAB_0019 — each in conjunction with a mycobacterial context term. Swept 2026-09-07.

PublicationJournalYear
Molecular Mechanisms Underlying Antimicrobial Resistance in Mycobacteria. doi:10.3390/ijms27156893 Int J Mol Sci 2026
Whole-genome sequencing reveals lineage-associated drug resistance and enables machine learning-based prediction in Mycobacterium tuberculosis clinical isolates. doi:10.3389/fmicb.2026.1828991 Front Microbiol 2026
Rapid Extensively Drug-Resistant (XDR) TB Diagnosis: An In-House DNA Biochip for Drug Resistance Detection and Mutation Profiling of Mycobacterium tuberculosis. doi:10.1155/cjid/5518992 Can J Infect Dis Med Microbiol 2026
Fluoroquinolone resistance and mutation profiles in Mycobacterium tuberculosis through whole genome sequencing in Fujian province, China. doi:10.3389/fpubh.2026.1890292 Front Public Health 2026
Alarming levels of fluoroquinolone resistance among MDR-TB patients in Poland: molecular and phenotypic analysis. doi:10.3389/fcimb.2026.1881444 Front Cell Infect Microbiol 2026
Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis. doi:10.1371/journal.pone.0352863 PLoS One 2026
Rapid Detection of Resistance Mutations in Multidrug-Resistant Tuberculosis With GenoType MTBDRsl Assay. doi:10.1155/pm/6993694 Pulm Med 2026
Assessing Corynebacterium glutamicum as a surrogate of Mycobacterium tuberculosis for DNA gyrase inhibitor design. doi:10.64898/2026.06.24.734172 bioRxiv 2026
Gemifloxacin resistance in Mycobacterium tuberculosis without QRDR mutations in gyrA or gyrB: evidence for non-canonical resistance mechanisms. doi:10.1128/spectrum.03710-25 names it Microbiol Spectr 2026
Fluoroquinolones as the linchpin of tuberculosis therapy: contrasting efficacy and resistance profiles in Mycobacterium tuberculosis versus Mycobacterium abscessus. doi:10.3389/fcimb.2026.1833650 Front Cell Infect Microbiol 2026
Routine Molecular Surveillance of Drug-Resistant Tuberculosis: Translating Mutation Proxies into Clinical Governance Intelligence in Rural Eastern Cape. doi:10.3390/healthcare14101280 Healthcare (Basel) 2026
Assessment of Antimicrobial Resistance in M. leprae Strains From Kiribati. doi:10.1111/tmi.70146 Trop Med Int Health 2026
Assessing fluoroquinolone resistance in Mycobacterium tuberculosis using nanopore sequencing: concordance with established diagnostic methods. doi:10.1007/s15010-026-02798-8 Infection 2026
Exploring Novel Gene Mutations Associated with Fluoroquinolone Resistance in Mycobacterium tuberculosis: Gene Sequencing Results from 275 Clinical Isolates in Chongqing, China. doi:10.2147/IDR.S590990 Infect Drug Resist 2026
Frequency, genetic mechanisms and factors associated with fluoroquinolone (pre-XDR) and aminoglycoside resistance among multidrug-resistant tuberculosis cases in Northwestern Nigeria. doi:10.1186/s12879-026-13191-z BMC Infect Dis 2026
Development of a point-of-care dual one-step recombinase-aided PCR assay for rapid identification of Mycobacterium tuberculosis gyrA mutations conferring fluoroquinolone resistance. doi:10.3389/fmicb.2026.1772984 names it Front Microbiol 2026
Stepwise evolution and clonal enrichment of gepotidacin resistance in Neisseria gonorrhoeae. doi:10.1128/aac.01706-25 Antimicrob Agents Chemother 2026
Multicentre field evaluation of Xpert MTB/XDR in sub-Saharan Africa. doi:10.1183/23120541.00427-2025 ERJ Open Res 2026
In Silico Design of gRNA for CRISPR System for Detection of Multidrug Resistant Tuberculosis Using Indian Mycobacterium tuberculosis Genomes: A Computational Study. doi:10.7759/cureus.101851 Cureus 2026
First insight of characteristics and prediction of Mycobacterium tuberculosis drug resistance by whole genome sequencing in Fujian Province, China. doi:10.1038/s41598-026-40398-6 Sci Rep 2026
iFIND INH/FQ: a LC-aNAAT assay for rapid simultaneous detection of isoniazid and fluoroquinolone resistance in Mycobacterium tuberculosis. doi:10.1128/spectrum.03743-25 Microbiol Spectr 2026
In Vitro Activity of Zoliflodacin Against Neisseria gonorrhoeae Isolates from Shanghai, China (2020-2023). doi:10.3390/antibiotics15010061 Antibiotics (Basel) 2026
Resistance to anti-leprosy drugs in multi-bacillary leprosy patients: The need for transformative action. doi:10.25259/IJDVL_1842_2024 Indian J Dermatol Venereol Leprol 2026
Genomic determinants of antibiotic resistance for Helicobacter pylori treatment: a retrospective phenotypic and genotypic observational study. doi:10.1016/j.lanmic.2025.101217 Lancet Microbe 2026
Geographical trends of drug-resistant strains of Mycobacterium leprae in TLM hospitals: insights from a four-year study across eleven hospitals in eight Indian States. doi:10.1007/s10096-025-05351-x Eur J Clin Microbiol Infect Dis 2026
Machine learning approaches to predict drug resistance in tuberculosis. doi:10.1016/j.compbiolchem.2025.108705 Comput Biol Chem 2026
Metagenomic insights into the urban-rural variation of antimicrobial resistance and pathogen reservoirs in untreated wastewater from central India. doi:10.3389/fmicb.2025.1722229 Front Microbiol 2025
Artificial intelligence for screening drug resistance in tuberculosis. doi:10.25259/IJMR_1546_2025 Indian J Med Res 2025
The microevolutionary trajectory of endemic multidrug-resistant tuberculosis strains in Portugal toward increased drug resistance levels and its clinical significance. doi:10.3389/fmicb.2025.1716549 Front Microbiol 2025
Genomic Surveillance of 3R Genes Associated with Antibiotic Resistance in Mycobacterium tuberculosis Isolates from Kazakhstan. doi:10.3390/antibiotics15010026 Antibiotics (Basel) 2025
Unraveling Drug Resistance in Mycobacterium leprae: Exploring Genetic Mutations to Enhance Treatment Strategies for Human Leprosy-A Narrative Review. doi:10.1155/ijm/7204337 Int J Microbiol 2025
Deciphering the population dynamics and drug-resistance characteristics of extrapulmonary tuberculosis: genomic and clinical insights from a Chinese hospital. doi:10.3389/fcimb.2025.1692783 Front Cell Infect Microbiol 2025
Drug resistance profile of Mycobacterium tuberculosis in China: update until 2024. doi:10.3389/fmicb.2025.1697490 Front Microbiol 2025
A novel one-tube nested fluorescence melting curve analysis for rapid detection of drug-resistant Mycobacterium tuberculosis. doi:10.1186/s12866-025-04601-4 BMC Microbiol 2025
Genotypic investigation of Mycobacterium leprae in patients with relapsing leprosy in Mato Grosso, Brazil. doi:10.1007/s00430-025-00864-w Med Microbiol Immunol 2025
Evaluation of multiplex allele-specific PCR for rapid detection of isoniazid and fluoroquinolone resistance in Mycobacterium tuberculosis: A cross-sectional study in high-TB-burden settings in India. doi:10.1016/j.ijtb.2025.06.007 Indian J Tuberc 2025
Whole genome sequencing-based detection of extensively drug-resistant tuberculosis from Ethiopia. doi:10.1038/s43856-025-01271-1 Commun Med (Lond) 2025
Fluoroquinolone and Second-Line Injectable Resistance Among Rifampicin- and Isoniazid-Resistant Mycobacterium tuberculosis Clinical Isolates: A Molecular Study from a High-Burden Setting. doi:10.3390/microorganisms13112470 Microorganisms 2025
Molecular Epidemiology of Mycobacterium tuberculosis in Mexico. doi:10.3390/microorganisms13112453 Microorganisms 2025
Therapeutic failure of multidrug therapy for leprosy: A retrospective case series in a hyperendemic Brazilian City. doi:10.1371/journal.pntd.0013616 PLoS Negl Trop Dis 2025
Indole-containing inhibitors with improved efficacy targeting the gyrase of Mycobacterium tuberculosis. doi:10.1093/narmme/ugae027 NAR Mol Med 2025
In Vitro Activity of Sulfamethoxazole-Trimethoprim, Amikacin, Oxazolidinones, Fluoroquinolones and Fidaxomicin against Isolates of Nocardia. doi:10.1021/acsomega.5c02351 ACS Omega 2025
Mutations in gyrA and gyrB among drug-resistant Mycobacterium tuberculosis isolates in South Korea. doi:10.1016/j.meegid.2025.105849 names it Infect Genet Evol 2025
Antimicrobial susceptibility patterns and genotypic characteristics of Mycobacterium marinum and Mycobacterium abscessus isolated from cutaneous infections: A retrospective study. doi:10.1016/j.jgar.2025.10.001 J Glob Antimicrob Resist 2025
Deciphering the Role of pafBC in Mycobacteriophage Resistance and Biofilm Formation. doi:10.1021/acsinfecdis.5c00627 ACS Infect Dis 2025
Population structure and antibiotic resistance profiles of Mycobacterium tuberculosis isolates from Ibadan, Nigeria (2019-2020): a pilot study to improve affordable molecular diagnostic tools. doi:10.3389/fpubh.2025.1657825 Front Public Health 2025
Genomic insights into pyrazinamide and fluoroquinolone resistance in multidrug-resistant tuberculosis in Khyber Pakhtunkhwa, Pakistan. doi:10.1016/j.ijmm.2025.151674 Int J Med Microbiol 2025
Diagnostics and new treatment regimens for TB: can the Xpert MTB/XDR assay fill the gap for fluoroquinolone testing? doi:10.1128/jcm.00643-25 J Clin Microbiol 2025
Whole-genome sequencing and machine learning reveal key drivers of delayed sputum conversion in rifampicin-resistant tuberculosis. doi:10.3389/fcimb.2025.1641385 Front Cell Infect Microbiol 2025
Surveillance and analysis of drug resistance and drug resistance levels in multidrug resistant tuberculosis on the tropical islands of China. doi:10.1186/s12879-025-11312-8 BMC Infect Dis 2025
Rapid screening of mutations for second-line-drug-resistant genes in Mycobacterium tuberculosis culture isolates by in-house developed DNA bio-chip. doi:10.1007/s10096-025-05221-6 Eur J Clin Microbiol Infect Dis 2025
Whole-genome sequencing for analyzing the transmission characteristics of drug-resistant Mycobacterium tuberculosis in Ganzhou, China. doi:10.1186/s12879-025-11356-w BMC Infect Dis 2025
Lineage identification and mutation profile of Mycobacterium tuberculosis: A study from National Reference Laboratory, India. doi:10.1016/j.ijmmb.2025.100925 Indian J Med Microbiol 2025
Nanopore-based targeted sequencing (NTS) for drug-resistant tuberculosis: an integrated tool for personalized treatment strategies and guidance for new drug development. doi:10.1186/s12879-025-11227-4 BMC Infect Dis 2025
Prevalence and molecular characterization of drug-resistant Mycobacterium tuberculosis in Heyuan City in China. doi:10.3389/fcimb.2025.1586938 Front Cell Infect Microbiol 2025
Molecular Detection of Gene Mutation Related to Drug Resistance in Mycobacterium leprae. doi:10.4103/ijmy.ijmy_35_25 Int J Mycobacteriol 2025
Unearthing novel mutations and genetic variation in drug sensitive and resistant isolates of Mycobacterium tuberculosis through whole genome sequencing: A study from eastern Uttar Pradesh, India. doi:10.1016/j.ijmmb.2025.100895 Indian J Med Microbiol 2025
An exploratory study on the application of nanopore sequencing for detecting Mycobacterium tuberculosis drug resistance in respiratory specimens. doi:10.1186/s12890-025-03747-1 BMC Pulm Med 2025
Identification and quantification of gyrA variants in fluoroquinolone-resistant Mycobacterium tuberculosis in a MeltArray reaction. doi:10.1128/jcm.00146-25 names it J Clin Microbiol 2025
The mutant selection window of moxifloxacin and bedaquiline resistant Mycobacterium tuberculosis. doi:10.1016/j.jinf.2025.106523 J Infect 2025
Patterns of Mycobacterium tuberculosis genotypes and resistance mutations in patients with pulmonary multidrug-resistant tuberculosis in Sverdlovsk Oblast, Russia. doi:10.3389/ftubr.2025.1406536 Front Tuberc 2025
Genotypic analysis of drug-resistant tuberculosis in Ghana: Insights into pre-XDR and XDR-TB. doi:10.1371/journal.pone.0323527 PLoS One 2025
Classic and new candidate markers for drug resistance in a large cohort of leprosy patients from the Amazon state, Brazil. doi:10.1128/aac.01550-24 Antimicrob Agents Chemother 2025
Whole-genome sequencing analysis to identify antimicrobial resistance regions and virulence factors in Mycobacterium tuberculosis isolates from the Amhara Region, Ethiopia. doi:10.1038/s41598-025-01241-6 Sci Rep 2025
Performance of a molecular beacon-based qPCR method for detection of fluoroquinolone resistance in Mycobacterium tuberculosis: A study confirmed by sequencing. doi:10.1016/j.diagmicrobio.2025.116865 Diagn Microbiol Infect Dis 2025
Multi-drug resistance and compensatory mutations in Mycobacterium tuberculosis in Vietnam. doi:10.1111/tmi.14104 Trop Med Int Health 2025
Prevalence and Genetic Profiling of Second-line Drug Resistant Tuberculosis at the Tertiary Care Center of Northern India. doi:10.1007/s00284-025-04152-x Curr Microbiol 2025
Whole genomic analysis uncovers high genetic diversity of rifampicin-resistant Mycobacterium tuberculosis strains in Botswana. doi:10.3389/fmicb.2025.1535160 Front Microbiol 2025
Genetic diversity and transmission pattern of multidrug-resistant tuberculosis based on whole-genome sequencing in Wuhan, China. doi:10.3389/fpubh.2025.1442987 Front Public Health 2025
Study of fluoroquinolones resistance in rifampicin-resistant tuberculosis patients in Beijing: Characteristics, trends, and treatment outcomes. doi:10.1002/ame2.12505 Animal Model Exp Med 2025
Genotypic and phenotypic diversity of Mycobacterium tuberculosis strains from eastern India. doi:10.1016/j.meegid.2025.105713 Infect Genet Evol 2025
Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis. doi:10.1371/journal.pone.0315512 PLoS One 2025
Population genetic analysis of clinical Mycobacterium abscessus complex strains in China. doi:10.3389/fcimb.2024.1496896 Front Cell Infect Microbiol 2024
An Approach to Identifying Single-Nucleotide Mutations Using Noncovalent Associates of Gold Nanoparticles with Fluorescently Labeled Oligonucleotides. doi:10.3390/ijms252413230 Int J Mol Sci 2024
Identification of Anti-Tuberculosis Drugs Targeting DNA Gyrase A and Serine/Threonine Protein Kinase PknB: A Machine Learning-Assisted Drug-Repurposing Approach. doi:10.3390/tropicalmed9120288 Trop Med Infect Dis 2024
Evaluation of Tridax procumbens Secondary Metabolites Anti-Tuberculosis Activity by In Vitro and In Silico Methods. doi:10.1007/s00284-024-04033-9 Curr Microbiol 2024
Structural Aspects of Mycobacterium tuberculosis DNA Gyrase Targeted by Novel Bacterial Topoisomerase Inhibitors. doi:10.1021/acsmedchemlett.4c00447 ACS Med Chem Lett 2024
Mycobacterium tuberculosis evolution from monoresistance to pre-extensive drug resistance during a prolonged household outbreak. doi:10.1016/j.jctube.2024.100482 J Clin Tuberc Other Mycobact Dis 2024
Genetic diversities and drug resistance in Mycobacterium bovis isolates from zoonotic tuberculosis using whole genome sequencing. doi:10.1186/s12864-024-10909-8 BMC Genomics 2024
Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis. doi:10.1128/aac.00583-24 Antimicrob Agents Chemother 2024
The catalogue of Mycobacterium tuberculosis mutations associated with drug resistance to 12 drugs in China from a nationwide survey: a genomic analysis. doi:10.1016/S2666-5247(24)00131-9 Lancet Microbe 2024
High frequency of silent mutations in gyrA gene of Mycobacterium tuberculosis in Indian isolates. doi:10.1002/em.22629 names it Environ Mol Mutagen 2024
Risk assessment and transmission of fluoroquinolone resistance in drug-resistant pulmonary tuberculosis: a retrospective genomic epidemiology study. doi:10.1038/s41598-024-70535-y Sci Rep 2024
Epidemiology and molecular characterization of Mycobacterium tuberculosis including a drug-resistant strain associated with mortality of Asian elephants in Nepal 2019-2022. doi:10.1016/j.tube.2024.102550 Tuberculosis (Edinb) 2024
Pattern and characteristics of mutations conferring resistance to second line drugs in Mycobacterium tuberculosis isolates of pulmonary and extrapulmonary TB samples. doi:10.1016/j.ijtb.2023.07.003 Indian J Tuberc 2024
Drug-Resistant Profiles and Genetic Diversity of Mycobacterium Tuberculosis Revealed by Whole-Genome Sequencing in Hinggan League of Inner Mongolia, China. doi:10.2147/IDR.S466197 Infect Drug Resist 2024
New generation fluoroquinolone sitafloxacin could potentially overcome the majority levofloxacin and moxifloxacin resistance in multidrug-resistant Mycobacterium tuberculosis. doi:10.1099/jmm.0.001825 J Med Microbiol 2024
New insight in molecular detection of Mycobacterium tuberculosis. doi:10.1186/s13568-024-01730-3 AMB Express 2024
Evaluation of genetic correlation with fluoroquinolones resistance in rifampicin-resistant Mycobacterium tuberculosis isolates. doi:10.1016/j.heliyon.2024.e31959 Heliyon 2024
Drug-Resistant Characteristics, Genetic Diversity, and Transmission Dynamics of Multidrug-Resistant Mycobacterium tuberculosis in Jiangxi, China. doi:10.2147/IDR.S460267 Infect Drug Resist 2024
Emergence of Neisseria gonorrhoeae Clone with Reduced Susceptibility to Sitafloxacin in China: An In Vitro and Genomic Study. doi:10.3390/antibiotics13050468 Antibiotics (Basel) 2024
Acquired bedaquiline and fluoroquinolones resistance during treatment follow-up in Oromia Region, North Shewa, Ethiopia. doi:10.1016/j.idcr.2024.e01988 IDCases 2024
Genotypic and phenotypic drug resistance patterns of Mycobacterium tuberculosis isolated from presumptive pulmonary tuberculosis patients in Ethiopia: A multicenter study. doi:10.1371/journal.pone.0303460 PLoS One 2024
Signal Propagation in the ATPase Domain of Mycobacterium tuberculosis DNA Gyrase from Dynamical-Nonequilibrium Molecular Dynamics Simulations. doi:10.1021/acs.biochem.4c00161 Biochemistry 2024
Drug-resistant Mycobacterium tuberculosis among Nepalese patients at a tuberculosis referral center. doi:10.1371/journal.pone.0301210 PLoS One 2024
Identification of positively selected genes in Mycobacterium tuberculosis from southern Xinjiang Uygur autonomous region of China. doi:10.3389/fmicb.2024.1290227 Front Microbiol 2024
Efflux pump effects on levofloxacin resistance in Mycobacterium abscessus. doi:10.1128/aac.01348-23 Antimicrob Agents Chemother 2024
Patterns and profiles of drug resistance-conferring mutations in Mycobacterium tuberculosis genotypes isolated from tuberculosis-suspected attendees of spiritual holy water sites in Northwest Ethiopia. doi:10.3389/fpubh.2024.1356826 Front Public Health 2024
Whole Genome Sequence-Based Analyses of Drug Resistance Characteristics, Genetic Diversity, and Transmission Dynamics of Drug-Resistant Mycobacterium tuberculosis in Urumqi City. doi:10.2147/IDR.S454913 Infect Drug Resist 2024
Recent dynamics in Neisseria gonorrhoeae genomic epidemiology in Brazil: antimicrobial resistance and genomic lineages in 2017-20 compared to 2015-16. doi:10.1093/jac/dkae075 J Antimicrob Chemother 2024
[Determination Of Related Genetic Variations Resistance To Moxifloxacin From Mycobacterium Tuberculosis Strain In Hanoi From 2020 - 2022]. doi:10.51403/0868-2836/2023/1461 Tap Chi Y Hoc Du Phong 2024
Rapid detection of multidrug resistance in tuberculosis using nanopore-based targeted next-generation sequencing: a multicenter, double-blind study. doi:10.3389/fmicb.2024.1349715 Front Microbiol 2024
Mutational Dynamics Related to Antibiotic Resistance in M. tuberculosis Isolates from Serial Samples of Patients with Tuberculosis and Type 2 Diabetes Mellitus. doi:10.3390/microorganisms12020324 Microorganisms 2024
Phenotypic and Genotypic Drug Resistance of Mycobacterium tuberculosis Strains Isolated from HIV-Infected Patients from a Third-Level Public Hospital in Mexico. doi:10.3390/pathogens13020098 Pathogens 2024
Whole genome sequencing for the prediction of resistant tuberculosis strains from northern India. doi:10.1016/j.ijmmb.2024.100537 Indian J Med Microbiol 2024
Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand. doi:10.1128/spectrum.03462-23 Microbiol Spectr 2024
Novel mutations found in Mycobacterium leprae DNA repair gene nth from central India. doi:10.1016/j.jiac.2023.12.011 J Infect Chemother 2024
Genetic stability of Mycobacterium abscessus during antibiotic treatment. doi:10.1016/j.jgar.2023.12.004 J Glob Antimicrob Resist 2024
High frequency of isoniazid and fluroquinolone resistance among patients with rifampicin sensitive tuberculosis. doi:10.1016/j.diagmicrobio.2023.116159 Diagn Microbiol Infect Dis 2024
The emerging threat of fluroquinolone-, bedaquiline-, and linezolid-resistant Mycobacterium tuberculosis in China: Observations on surveillance data. doi:10.1016/j.jiph.2023.11.018 J Infect Public Health 2024
Water network chemistry to exploit the nature of catalytic water molecules in Mtb DNA gyrase: a computational study to understand the binding mechanism of fluoroquinolones. doi:10.1080/07391102.2023.2199869 J Biomol Struct Dyn 2024
Impact of Whole-Genome Sequencing of Mycobacterium tuberculosis on Treatment Outcomes for MDR-TB/XDR-TB: A Systematic Review. doi:10.3390/pharmaceutics15122782 Pharmaceutics 2023
A precision overview of genomic resistance screening in Ecuadorian isolates of Mycobacterium tuberculosis using web-based bioinformatics tools. doi:10.1371/journal.pone.0294670 PLoS One 2023
Direct Detection of Fluoroquinolone Resistance in Sputum Samples from Tuberculosis Patients by High Resolution Melt Curve Analysis. doi:10.1007/s00284-023-03519-2 Curr Microbiol 2023
Comparison of the in vitro antibacterial activity of ofloxacin, levofloxacin, moxifloxacin, sitafloxacin, finafloxacin, and delafloxacin against Mycobacterium tuberculosis strains isolated in China. doi:10.1016/j.heliyon.2023.e21216 Heliyon 2023
Systematic investigation of the emerging pathogen of Tsukamurella species in a Chinese tertiary teaching hospital. doi:10.1128/spectrum.01644-23 Microbiol Spectr 2023
Amino acid 17 in QRDR of Gyrase A plays a key role in fluoroquinolones susceptibility in mycobacteria. doi:10.1128/spectrum.02809-23 Microbiol Spectr 2023
Antimicrobial Resistance and Molecular Typing of Neisseria gonorrhoeae Isolates From the Eastern Cape Province in South Africa. doi:10.1097/OLQ.0000000000001877 Sex Transm Dis 2023
Re-evaluation of critical concentrations of antituberculosis fluoroquinolones in the Mycobacteria Growth Indicator Tube 960 system. doi:10.4103/ijmy.ijmy_144_23 Int J Mycobacteriol 2023
Genotype MTBDRsl version 2 and phenotypic drug resistance detection of Mycobacterium tuberculosis for fluoroquinolones and aminoglycosides. doi:10.4103/ijmy.ijmy_120_23 Int J Mycobacteriol 2023
Fluoroquinolone resistance mutations among Mycobacterium tuberculosis and their interconnection with treatment outcome. doi:10.4103/ijmy.ijmy_116_23 Int J Mycobacteriol 2023
Genetic surveillance and outcomes of pyrazinamide and fluoroquinolones-resistant tuberculosis in Taiwan. doi:10.1016/j.jmii.2023.08.013 J Microbiol Immunol Infect 2023
Molecular Analysis of Anti-Tuberculosis Drug Resistance of Mycobacterium tuberculosis Isolated in the Republic of Korea. doi:10.3390/antibiotics12081324 Antibiotics (Basel) 2023
Whole genome sequencing of drug resistance Mycobacterium tuberculosis from extra-pulmonary sites. doi:10.26508/lsa.202302076 Life Sci Alliance 2023
Correlating clinical breakpoint concentration of moxifloxacin with gyrA mutations using the GenoType MTBDRsl assay Version 2.0. doi:10.1016/j.ijtb.2022.11.004 names it Indian J Tuberc 2023
Whole Genomic Analysis Revealed High Genetic Diversity and Drug-Resistant Characteristics of Mycobacterium tuberculosis in Guangxi, China. doi:10.2147/IDR.S410828 Infect Drug Resist 2023
Deciphering the emerging role of phytocompounds: Implications in the management of drug-resistant tuberculosis and ATDs-induced hepatic damage. doi:10.1016/j.jiph.2023.07.016 J Infect Public Health 2023
Characterization of Genetic Mutations in Multi-Drug-Resistant Isolates of Mycobacterium tuberculosis Bacilli Conferring Resistance to a Second-Line Anti-tuberculosis Drug. doi:10.7759/cureus.40442 Cureus 2023
Rapid detection of fluoroquinolone resistance in Mycobacterium tuberculosis using a novel multienzyme isothermal rapid assay. doi:10.1038/s41429-023-00639-6 J Antibiot (Tokyo) 2023
Resistance Profiles to Second-Line Anti-Tuberculosis Drugs and Their Treatment Outcomes: A Three-Year Retrospective Analysis from South India. doi:10.3390/medicina59061005 Medicina (Kaunas) 2023
Whole-genome sequencing reveals genotypic resistance in phenotypically susceptible Mycobacterium tuberculosis clinical isolates. doi:10.4103/ijmy.ijmy_101_23 Int J Mycobacteriol 2023
Hi-plex deep amplicon sequencing for identification, high-resolution genotyping and multidrug resistance prediction of Mycobacterium leprae directly from patient biopsies by using Deeplex Myc-Lep. doi:10.1016/j.ebiom.2023.104649 EBioMedicine 2023
Comparison of the Diagnostic Performance of MeltPro and Next-Generation Sequencing in Determining Fluoroquinolone Resistance in Multidrug-Resistant Tuberculosis Isolates. doi:10.1016/j.jmoldx.2023.02.003 J Mol Diagn 2023
Profile and Frequency of Mutations Conferring Drug-Resistant Tuberculosis in the Central, Southeastern and Eastern Ethiopia. doi:10.2147/IDR.S408567 Infect Drug Resist 2023
Mycobacterium tuberculosis Intra-Host Evolution Among Drug-Resistant Tuberculosis Patients Failing Treatment. doi:10.2147/IDR.S408976 Infect Drug Resist 2023
Distinct subunit architecture and assembly pattern of DNA gyrase from mycobacteria. doi:10.1111/mmi.15068 Mol Microbiol 2023
Emergence and evolution of drug-resistant Mycobacterium tuberculosis in eastern China: A six-year prospective study. doi:10.1016/j.ygeno.2023.110640 Genomics 2023
Strain diversity in Mycobacterium avium subsp. paratuberculosis-positive bovine fecal samples collected in Switzerland. doi:10.3389/fvets.2023.1154516 Front Vet Sci 2023
Evaluation of genetic mutations associated with phenotypic resistance to fluoroquinolones, bedaquiline, and linezolid in clinical Mycobacterium tuberculosis: A systematic review and meta-analysis. doi:10.1016/j.jgar.2023.05.001 J Glob Antimicrob Resist 2023
Comprehensive Drug Resistance Characterization of Pulmonary Tuberculosis in Algeria: Insights on Mycobacterium tuberculosis Strains by Whole-Genome Sequencing. doi:10.1089/mdr.2022.0321 Microb Drug Resist 2023
Evaluation of Microsphere-based xMAP Test for gyrA Mutation Identification in Mycobacterium Tuberculosis. doi:10.3967/bes2023.046 names it Biomed Environ Sci 2023
Characterization of DNA Gyrase Activity and Elucidation of the Impact of Amino Acid Substitution in GyrA on Fluoroquinolone Resistance in Mycobacterium avium. doi:10.1128/spectrum.05088-22 names it Microbiol Spectr 2023
Simplified cloning and isolation of peptides from "sandwiched" SUMO-peptide-intein fusion proteins. doi:10.1186/s12896-023-00779-5 BMC Biotechnol 2023
Advantages of analysing both pairwise SNV-distance and differing SNVs between Mycobacterium tuberculosis isolates for recurrent tuberculosis cause determination. doi:10.1099/mgen.0.000956 Microb Genom 2023
Endogenous relapse and exogenous reinfection in recurrent pulmonary tuberculosis: A retrospective study revealed by whole genome sequencing. doi:10.3389/fmicb.2023.1115295 Front Microbiol 2023
Whole-genome sequencing-based analyses of drug-resistant Mycobacterium tuberculosis from Taiwan. doi:10.1038/s41598-023-29652-3 Sci Rep 2023
Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort. doi:10.1128/jcm.01478-22 J Clin Microbiol 2023
MTBDRplus and MTBDRsl for simultaneous diagnosis of gastrointestinal tuberculosis and detection of first-line and second-line drug resistance. doi:10.1111/jgh.16124 J Gastroenterol Hepatol 2023
Molecular Characterization of Resistance to Second-Line Anti-Mycobacterial Drugs among Clinical Isolates of Multidrug-Resistant Mycobacterium tuberculosis. doi:10.7754/Clin.Lab.2022.220211 Clin Lab 2023
Strain diversity and gene mutations associated with presumptive multidrug-resistant Mycobacterium tuberculosis complex isolates in Northwest Ethiopia. doi:10.1016/j.jgar.2022.11.012 J Glob Antimicrob Resist 2023
GenoType MTBDRsl for detection of second-line drugs and ethambutol resistance in multidrug-resistant Mycobacterium tuberculosis isolates at a high-throughput laboratory. doi:10.1016/j.diagmicrobio.2022.115856 Diagn Microbiol Infect Dis 2023
Resistance patterns among drug-resistant tuberculosis patients and trends-over-time analysis of national surveillance data in Gabon, Central Africa. doi:10.1007/s15010-022-01941-5 Infection 2023
Drug resistance profiles and related gene mutations in slow-growing non-tuberculous mycobacteria isolated in regional tuberculosis reference laboratories of Iran: a three year cross-sectional study. doi:10.1080/20477724.2022.2049029 Pathog Glob Health 2023
The past, present and future of tuberculosis treatment. doi:10.3724/zdxbyxb-2022-0454 Zhejiang Da Xue Xue Bao Yi Xue Ban 2022
Analysis of drug resistance among difficult-to-treat tuberculosis patients in Ghana identifies several pre-XDR TB cases. doi:10.3389/fmicb.2022.1069292 Front Microbiol 2022
Comparative genome analysis reveals high-level drug resistance markers in a clinical isolate of Mycobacterium fortuitum subsp. fortuitum MF GZ001. doi:10.3389/fcimb.2022.1056007 Front Cell Infect Microbiol 2022
Genomic analysis of Mycobacterium tuberculosis variant bovis strains isolated from bovine in the state of Mato Grosso, Brazil. doi:10.3389/fvets.2022.1006090 Front Vet Sci 2022
High diversity of clinical Mycobacterium intracellulare in China revealed by whole genome sequencing. doi:10.3389/fpubh.2022.989587 Front Public Health 2022
Drug Resistance (Dapsone, Rifampicin, Ofloxacin) and Resistance-Related Gene Mutation Features in Leprosy Patients: A Systematic Review and Meta-Analysis. doi:10.3390/ijms232012443 Int J Mol Sci 2022
Pre-extensively drug-resistant tuberculosis among multidrug-resistant tuberculosis patients in Ethiopia: a laboratory-based surveillance study. doi:10.1016/j.ijregi.2022.08.012 IJID Reg 2022
Detection of Mutations in pncA in Mycobacterium tuberculosis Clinical Isolates from Nepal in Association with Pyrazinamide Resistance. doi:10.3390/cimb44090283 Curr Issues Mol Biol 2022
Drug susceptibility profiling and genetic determinants of drug resistance in Mycobacterium simiae isolates obtained from regional tuberculosis reference laboratories of Iran. doi:10.1371/journal.pone.0267320 PLoS One 2022
Molecular Surveillance of Antimicrobial Resistance of Mycobacterium leprae from Leprosy Patients in Zhejiang Province, China. doi:10.2147/IDR.S368682 Infect Drug Resist 2022
Investigating drug resistance of Mycobacterium leprae in the Comoros: an observational deep-sequencing study. doi:10.1016/S2666-5247(22)00117-3 Lancet Microbe 2022
Diagnostic utility of GenoType MTBDRsl assay for the detection of moxifloxacin-resistant mycobacterium tuberculosis, as compared to phenotypic method and whole-genome sequencing. doi:10.4103/ijmy.ijmy_70_22 Int J Mycobacteriol 2022
Sensitivity of different DNA extraction methods and PCR to detect resistance in patients with leprosy stratified by the bacilloscopic index. doi:10.1016/j.bjid.2022.102381 Braz J Infect Dis 2022
Ofloxacin resistance in multibacillary new leprosy cases from Purulia, West Bengal: a threat to effective secondary line treatment for rifampicin-resistant leprosy cases. doi:10.1016/j.jgar.2022.06.008 J Glob Antimicrob Resist 2022
[Exploratory study on detection of drug resistance of Mycobacterium tuberculosis in sputum specimens by next-generation sequencing]. doi:10.3760/cma.j.cn112147-20211104-00775 Zhonghua Jie He He Hu Xi Za Zhi 2022
Utility of line probe assay in detecting drug resistance and the associated mutations in patients with extrapulmonary tuberculosis in Addis Ababa, Ethiopia. doi:10.1177/20503121221098241 SAGE Open Med 2022
Application of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) in the detection of drug resistance of Mycobacterium tuberculosis in re-treated patients. doi:10.1016/j.tube.2022.102209 Tuberculosis (Edinb) 2022
First report of whole-genome analysis of an extensively drug-resistant Mycobacterium tuberculosis clinical isolate with bedaquiline, linezolid and clofazimine resistance from Uganda. doi:10.1186/s13756-022-01101-2 Antimicrob Resist Infect Control 2022
Performance of the GenoType MTBDRsl in a programmatic setting, South Africa. doi:10.5588/ijtld.21.0590 Int J Tuberc Lung Dis 2022
Spiropyrimidinetrione DNA Gyrase Inhibitors with Potent and Selective Antituberculosis Activity. doi:10.1021/acs.jmedchem.2c00266 J Med Chem 2022
Intra-host genetic population diversity: Role in emergence and persistence of drug resistance among Mycobacterium tuberculosis complex minor variants. doi:10.1016/j.meegid.2022.105288 Infect Genet Evol 2022
Utility of Multi-target Nested PCR and ELISPOT Assays for the Detection of Paucibacillary Leprosy: A Possible Conclusion of Clinical Laboratory Misdiagnosis. doi:10.3389/fcimb.2022.814413 Front Cell Infect Microbiol 2022
Characterization of Fluoroquinolone-Resistant and Multidrug-Resistant Mycobacterium tuberculosis Isolates Using Whole-Genome Sequencing in Tianjin, China. doi:10.2147/IDR.S361635 Infect Drug Resist 2022
Antimicrobial Resistance among Leprosy Patients in Brazil: Real-World Data Based on the National Surveillance Plan. doi:10.1128/aac.02170-21 Antimicrob Agents Chemother 2022
Molecular Epidemiology and Polymorphism Analysis in Drug-Resistant Genes in M. tuberculosis Clinical Isolates from Western and Northern India. doi:10.2147/IDR.S345855 Infect Drug Resist 2022
Molecular characterisation of second-line drug resistance among drug resistant tuberculosis patients tested in Uganda: a two and a half-year's review. doi:10.1186/s12879-022-07339-w BMC Infect Dis 2022
Application of Amplicon-Based Targeted NGS Technology for Diagnosis of Drug-Resistant Tuberculosis Using FFPE Specimens. doi:10.1128/spectrum.01358-21 Microbiol Spectr 2022
Whole-genome sequencing of Mycobacterium tuberculosis for prediction of drug resistance. doi:10.1017/S095026882100279X Epidemiol Infect 2022
Molecular Characterization of Mycobacterium ulcerans DNA Gyrase and Identification of Mutations Reducing Susceptibility to Quinolones In Vitro. doi:10.1128/AAC.01902-21 Antimicrob Agents Chemother 2022
Clinical and Microbiological Characteristics of Mycobacterium kansasii Pulmonary Infections in China. doi:10.1128/spectrum.01475-21 Microbiol Spectr 2022
Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in Mycobacterium tuberculosis from Individuals Diagnosed with Preextensive Drug-Resistant Tuberculosis. doi:10.1089/mdr.2021.0212 Microb Drug Resist 2022
A CRISPR-based nucleic acid detection platform (CRISPR-CPA): Application for detection of Nocardia farcinica. doi:10.1111/jam.15424 J Appl Microbiol 2022
Mutations associated with Helicobacter pylori antimicrobial resistance in the Ecuadorian population. doi:10.1111/jam.15396 J Appl Microbiol 2022
Whole-genome sequencing for surveillance of tuberculosis drug resistance and determination of resistance level in China. doi:10.1016/j.cmi.2021.09.014 Clin Microbiol Infect 2022
Equal rates of drug resistance in leprosy cases with relapse and recurrent/chronic Type 2 reaction: time to revise the guidelines for drug-resistance testing in leprosy? doi:10.1111/ced.14884 Clin Exp Dermatol 2022
DNA Methyltransferase HsdM Induce Drug Resistance on Mycobacterium tuberculosis via Multiple Effects. doi:10.3390/antibiotics10121544 Antibiotics (Basel) 2021
Whole Genome Sequencing of Drug Resistant and Drug Susceptible Mycobacterium tuberculosis Isolates From Tigray Region, Ethiopia. doi:10.3389/fmicb.2021.743198 Front Microbiol 2021
Performance of GenoType MTBDRsl assay for detection of second-line drugs and ethambutol resistance directly from sputum specimens of MDR-TB patients in Bangladesh. doi:10.1371/journal.pone.0261329 PLoS One 2021
Putative extensive and pre-extensive drug resistant-tuberculosis associated with unusual genotypes on the Thailand-Myanmar border. doi:10.1590/S1678-9946202163085 Rev Inst Med Trop Sao Paulo 2021
Strong Increase in Moxifloxacin Resistance Rate among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China, 2007 to 2013. doi:10.1128/Spectrum.00409-21 Microbiol Spectr 2021
Correlation of gyr Mutations with the Minimum Inhibitory Concentrations of Fluoroquinolones among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Bangladesh. doi:10.3390/pathogens10111422 Pathogens 2021
Analysis on Drug-Resistance-Associated Mutations among Multidrug-Resistant Mycobacterium tuberculosis Isolates in China. doi:10.3390/antibiotics10111367 Antibiotics (Basel) 2021
Characterizing the gene mutations associated with resistance to gatifloxacin in Mycobacterium tuberculosis through whole-genome sequencing. doi:10.1016/j.ijid.2021.09.028 Int J Infect Dis 2021
Prevalence of extensively drug-resistant tuberculosis in a Chinese multidrug-resistant TB cohort after redefinition. doi:10.1186/s13756-021-00995-8 Antimicrob Resist Infect Control 2021
Simultaneous Determination of Mycobacterium leprae Drug Resistance and Single-Nucleotide Polymorphism Genotype by Use of Nested Multiplex PCR with Amplicon Sequencing. doi:10.1128/JCM.00814-21 J Clin Microbiol 2021
Screening of Compounds for Anti-tuberculosis Activity, and in vitro and in vivo Evaluation of Potential Candidates. doi:10.3389/fmicb.2021.658637 Front Microbiol 2021
A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance. doi:10.1016/j.cmi.2021.07.007 Clin Microbiol Infect 2021
Genotypic diversity of multi- and pre-extremely drug-resistant Mycobacterium tuberculosis isolates from Morocco. doi:10.1371/journal.pone.0253826 PLoS One 2021
Mycobacterium setense isolated from a cat with atypical mycobacterial panniculitis. doi:10.1055/a-1528-1763 Tierarztl Prax Ausg K Kleintiere Heimtiere 2021
Whole-genome analysis of drug-resistant Mycobacterium tuberculosis reveals novel mutations associated with fluoroquinolone resistance. doi:10.1016/j.ijantimicag.2021.106385 Int J Antimicrob Agents 2021
Clinical implications of high-risk mutations in drug resistant tuberculosis (DR-TB): An observational cohort study. doi:10.1016/j.ijmmb.2021.05.020 Indian J Med Microbiol 2021
Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan. doi:10.1038/s41598-021-91757-4 Sci Rep 2021
Highly transmitted M. tuberculosis strains are more likely to evolve MDR/XDR and cause outbreaks, but what makes them highly transmitted? doi:10.1016/j.tube.2021.102092 Tuberculosis (Edinb) 2021
Distribution of fluoroquinolone resistance determinants in Carbapenem-resistant Klebsiella pneumoniae clinical isolates associated with bloodstream infections in China. doi:10.1186/s12866-021-02238-7 BMC Microbiol 2021
Computational modeling and bioinformatic analyses of functional mutations in drug target genes in Mycobacterium tuberculosis. doi:10.1016/j.csbj.2021.04.034 Comput Struct Biotechnol J 2021
Piperidine-4-Carboxamides Target DNA Gyrase in Mycobacterium abscessus. doi:10.1128/AAC.00676-21 Antimicrob Agents Chemother 2021
Comparative in vitro susceptibility of a novel fluoroquinolone antibiotic candidate WFQ-228, levofloxacin, and moxifloxacin against Mycobacterium tuberculosis. doi:10.1016/j.ijid.2021.04.036 Int J Infect Dis 2021
Increasing prevalence of resistance to second-line drugs among multidrug-resistant Mycobacterium tuberculosis isolates in Kuwait. doi:10.1038/s41598-021-87516-0 Sci Rep 2021
Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. doi:10.1186/s12879-021-06024-8 BMC Infect Dis 2021
Molecular Characteristics and Drug Resistance of Mycobacterium tuberculosis Isolate Circulating in Shaanxi Province, Northwestern China. doi:10.1089/mdr.2020.0496 Microb Drug Resist 2021
Exploratory development of PCR-fluorescent probes in rapid detection of mutations associated with extensively drug-resistant tuberculosis. doi:10.1007/s10096-021-04236-z Eur J Clin Microbiol Infect Dis 2021
Molecular characterization of mutations associated with resistance to second line drugs in Mycobacterium tuberculosis patients from Casablanca, Morocco. doi:10.1590/S1678-9946202163019 Rev Inst Med Trop Sao Paulo 2021
Resistance to Second-Line Anti-TB Drugs in Cambodia: A Phenotypic and Genetic Study. doi:10.2147/IDR.S289907 Infect Drug Resist 2021
Molecular epidemiology of Mycobacterium tuberculosis in adult Filipino TB-HIV co-infected patients. doi:10.5588/ijtld.20.0878 Int J Tuberc Lung Dis 2021
Clinical outcomes and molecular characterization of drug-resistant tuberculosis in pre- and extensively drug-resistant disease based on line probe assays. doi:10.1016/j.bjid.2021.101544 Braz J Infect Dis 2021
Prevalence and molecular characterizations of seven additional drug resistance among multidrug-resistant tuberculosis in China: A subsequent study of a national survey. doi:10.1016/j.jinf.2021.02.004 J Infect 2021
Moxifloxacin Activates the SOS Response in Mycobacterium tuberculosis in a Dose- and Time-Dependent Manner. doi:10.3390/microorganisms9020255 Microorganisms 2021
Drug resistance gene mutations and treatment outcomes in MDR-TB: A prospective study in Eastern China. doi:10.1371/journal.pntd.0009068 PLoS Negl Trop Dis 2021
Drug-resistant Mycobacterium tuberculosis and its genotypes isolated from an outbreak in western Thailand. doi:10.1093/trstmh/traa148 Trans R Soc Trop Med Hyg 2021
Genotyping and Molecular Characterization of Fluoroquinolone's Resistance Among Multidrug-Resistant Mycobacterium tuberculosis in Southwest of China. doi:10.1089/mdr.2019.0339 Microb Drug Resist 2021
Frequency and patterns of first- and second-line drug resistance-conferring mutations in Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients in a cross-sectional study in Tigray Region, Ethiopia. doi:10.1016/j.jgar.2020.11.017 J Glob Antimicrob Resist 2021
An explainable machine learning platform for pyrazinamide resistance prediction and genetic feature identification of Mycobacterium tuberculosis. doi:10.1093/jamia/ocaa233 J Am Med Inform Assoc 2021
Emergence of Specific gyrA Mutations Associated High-Level Fluoroquinolone-Resistant Mycobacterium tuberculosis among Multidrug-Resistant Tuberculosis Cases in North India. doi:10.1089/mdr.2020.0240 names it Microb Drug Resist 2021
Resistance-Conferring Mutations on Whole-Genome Sequencing of Fluoroquinolone-resistant and -Susceptible Mycobacterium tuberculosis Isolates: A Proposed Threshold for Identifying Resistance. doi:10.1093/cid/ciaa496 Clin Infect Dis 2021
Simultaneous Detection of Drug-resistant Mutations in Mycobacterium tuberculosis and Determining their Role through In Silico Docking. doi:10.2174/1871526520666200318111140 Infect Disord Drug Targets 2021
Whole-genome sequence analysis and comparisons between drug-resistance mutations and minimum inhibitory concentrations of Mycobacterium tuberculosis isolates causing M/XDR-TB. doi:10.1371/journal.pone.0244829 PLoS One 2020
Design, Synthesis and Pharmacological Evaluation of Some C(3) Heterocyclic-Substituted Ciprofloxacin Derivatives as Chimeric Antitubercular Agents. doi:10.1248/cpb.c20-00525 Chem Pharm Bull (Tokyo) 2020
Pulmonary infection due to fluoroquinolone-resistant Mycolicibacterium fortuitum: a case report. doi:10.1186/s12879-020-05596-1 BMC Infect Dis 2020
Molecular Evaluation of Fluoroquinolone Resistance in Serial Mycobacterium tuberculosis Isolates from Individuals Diagnosed with Multidrug-Resistant Tuberculosis. doi:10.1128/AAC.01663-20 Antimicrob Agents Chemother 2020
Laboratory Evaluation of a Lateral-Flow Cell for Molecular Detection of First-Line and Second-Line Antituberculosis Drug Resistance. doi:10.1128/JCM.01417-20 J Clin Microbiol 2020
Cascade of deoxyribozymes for the colorimetric analysis of drug resistance in Mycobacterium tuberculosis. doi:10.1016/j.bios.2020.112385 Biosens Bioelectron 2020
Sequence-based detection of first-line and second-line drugs resistance-associated mutations in Mycobacterium tuberculosis isolates in Isfahan, Iran. doi:10.1016/j.meegid.2020.104468 Infect Genet Evol 2020
Specific gyrA Gene Mutations Correlate with High Prevalence of Discordant Levofloxacin Resistance in Mycobacterium tuberculosis Isolates from Beijing, China. doi:10.1016/j.jmoldx.2020.06.010 names it J Mol Diagn 2020
Survey of drug resistance associated gene mutations in Mycobacterium tuberculosis, ESKAPE and other bacterial species. doi:10.1038/s41598-020-65766-8 Sci Rep 2020
Genotypic and phenotypic characterization of Mycobacterium tuberculosis resistance against fluoroquinolones in the northeast of Iran. doi:10.1186/s12879-020-05112-5 BMC Infect Dis 2020
Genomic signatures of drug resistance in highly resistant Mycobacterium tuberculosis strains of the early ancient sublineage of Beijing genotype in Russia. doi:10.1016/j.ijantimicag.2020.106036 Int J Antimicrob Agents 2020
Genotype analysis of ofloxacin-resistant multidrug-resistant Mycobacterium tuberculosis isolates in a multicentered study from India. doi:10.4103/ijmr.IJMR_493_18 Indian J Med Res 2020
[Analysis on drug resistance-associated mutations of multi-drug resistant Mycobacterium tuberculosis based on whole-genome sequencing in China]. doi:10.3760/cma.j.cn112338-20191111-00800 Zhonghua Liu Xing Bing Xue Za Zhi 2020
Frequency of first and second-line drug resistance-associated mutations among resistant Mycobacterium tuberculosis clinical isolates from São Paulo, Brazil. doi:10.1590/0074-02760200055 Mem Inst Oswaldo Cruz 2020
Fluoroquinolone resistance and mutational profile of gyrA in pulmonary MDR tuberculosis patients. doi:10.1186/s12890-020-1172-4 names it BMC Pulm Med 2020
Detection of drug resistant Mycobacterium tuberculosis by high-throughput sequencing of DNA isolated from acid fast bacilli smears. doi:10.1371/journal.pone.0232343 PLoS One 2020
Bacterial population kinetics in heteroresistant Mycobacterium tuberculosis harbouring rare resistance-conferring mutations in gyrA and rpoB imply an epistatic interaction of mutations in a pre-XDR-TB patient. doi:10.1093/jac/dkaa109 names it J Antimicrob Chemother 2020
Artificial Intelligence and Machine learning based prediction of resistant and susceptible mutations in Mycobacterium tuberculosis. doi:10.1038/s41598-020-62368-2 Sci Rep 2020
Second-line Drug Resistance Characterization in Mycobacterium tuberculosis by Genotype MTBDRsl Assay. doi:10.2991/jegh.k.191215.003 J Epidemiol Glob Health 2020
Association Between the Phenotype and Genotype of Isoniazid Resistance Among Mycobacterium tuberculosis Isolates in Thailand. doi:10.2147/IDR.S242261 Infect Drug Resist 2020
Molecular characterisation of mutations associated with resistance to first- and second-line drugs among Indonesian patients with tuberculosis. doi:10.1016/j.jtumed.2019.12.003 J Taibah Univ Med Sci 2020
Metabolic Changes of Mycobacterium tuberculosis during the Anti-Tuberculosis Therapy. doi:10.3390/pathogens9020131 Pathogens 2020
Molecular characterization of pre-extensive drug resistant Mycobacterium tuberculosis in Northeast Brazil. doi:10.1590/S1678-9946202062004 Rev Inst Med Trop Sao Paulo 2020
Burden of baseline resistance of Mycobacterium tuberculosis to fluoroquinolones and second-line injectables in central India. doi:10.1093/trstmh/trz121 Trans R Soc Trop Med Hyg 2020
The molecular patterns of resistance to anti-tuberculosis drugs: an analysis from Istanbul, Turkey. doi:10.1080/1120009X.2020.1716477 J Chemother 2020
Increased prevalence of levofloxacin-resistant Mycobacterium tuberculosis in China is associated with specific mutations within the gyrA gene. doi:10.1016/j.ijid.2020.01.021 names it Int J Infect Dis 2020
Epidemiological cut-offs for Sensititre susceptibility testing of Mycobacterium tuberculosis: interpretive criteria cross validated with whole genome sequencing. doi:10.1038/s41598-020-57992-x Sci Rep 2020
Functional interactions between gyrase subunits are optimized in a species-specific manner. doi:10.1074/jbc.RA119.010245 J Biol Chem 2020
Evidence for Mycobacterium leprae Drug Resistance in a Large Cohort of Leprous Neuropathy Patients from India. doi:10.4269/ajtmh.19-0390 Am J Trop Med Hyg 2020
WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis. doi:10.1016/j.tube.2019.101891 Tuberculosis (Edinb) 2020
Bacillus Calmette-Guérin strains with defined resistance mutations: a new tool for tuberculosis laboratory quality control. doi:10.1016/j.cmi.2019.10.033 Clin Microbiol Infect 2020
The Genetic Background Modulates the Evolution of Fluoroquinolone-Resistance in Mycobacterium tuberculosis. doi:10.1093/molbev/msz214 Mol Biol Evol 2020
Emergence and Transmission of Drug-/Multidrug-resistant Mycobacterium leprae in a Former Leprosy Colony in the Brazilian Amazon. doi:10.1093/cid/ciz570 Clin Infect Dis 2020
Elucidation of drug resistance mutations in Mycobacterium tuberculosis isolates from North India by whole-genome sequencing. doi:10.1016/j.jgar.2019.05.019 J Glob Antimicrob Resist 2020
Evaluation of MTBDRsl for detecting resistance in Mycobacterium tuberculosis to second-line drugs. doi:10.5588/ijtld.18.0562 Int J Tuberc Lung Dis 2019
Phenotypic and genotypic characterization of levofloxacin- and moxifloxacin-resistant Mycobacterium tuberculosis clinical isolates in southern China. doi:10.21037/jtd.2019.11.03 J Thorac Dis 2019
Nested PCR and the TaqMan SNP Genotyping Assay enhanced the sensitivity of drug resistance testing of Mycobacterium leprae using clinical specimens of leprosy patients. doi:10.1371/journal.pntd.0007946 PLoS Negl Trop Dis 2019
Detection of Second Line Drug Resistance among Drug Resistant Mycobacterium Tuberculosis Isolates in Botswana. doi:10.3390/pathogens8040208 Pathogens 2019
Whole genome sequencing of drug resistant Mycobacterium tuberculosis isolates from a high burden tuberculosis region of North West Pakistan. doi:10.1038/s41598-019-51562-6 Sci Rep 2019
Molecular surveillance of antimicrobial resistance and transmission pattern of Mycobacterium leprae in Chinese leprosy patients. doi:10.1080/22221751.2019.1677177 Emerg Microbes Infect 2019
A multilocus sequence typing scheme for Mycobacterium abscessus complex (MAB-multilocus sequence typing) using whole-genome sequencing data. doi:10.4103/ijmy.ijmy_106_19 Int J Mycobacteriol 2019
A Rare D94F Change in gyrA Gene of Multidrug-Resistant Mycobacterium tuberculosis Possibly Contributing to an Unfavorable Treatment Outcome. doi:10.1128/AAC.01312-19 names it Antimicrob Agents Chemother 2019
Prevalence, risk and genetic characteristics of drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China. doi:10.2147/IDR.S209971 Infect Drug Resist 2019
Three-reaction high-resolution melting assay for rapid differentiation of Mycobacterium tuberculosis complex members. doi:10.1002/mbo3.919 Microbiologyopen 2019
Mutation and Transmission Profiles of Second-Line Drug Resistance in Clinical Isolates of Drug-Resistant Mycobacterium tuberculosis From Hebei Province, China. doi:10.3389/fmicb.2019.01838 Front Microbiol 2019
[Detection and Molecular Analysis of Moxifloxacin MIC Values of Mycobacterium tuberculosis Strains Isolated from Clinical Specimens]. doi:10.5578/mb.68291 Mikrobiyol Bul 2019
Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations. doi:10.1038/s41598-019-48289-9 Sci Rep 2019
DNA gyrase could be a crucial regulatory factor for growth and survival of Mycobacterium leprae. doi:10.1038/s41598-019-47364-5 Sci Rep 2019
Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014-2016). doi:10.1186/s12890-019-0891-x BMC Pulm Med 2019
Moxifloxacin resistance and genotyping of Mycobacterium avium and Mycobacterium intracellulare isolates in Japan. doi:10.1016/j.jiac.2019.05.028 J Infect Chemother 2019
Diagnostic predictive values of the Hain genotype MTBDRsl assay in mycobacterial strains isolated from Sudan. doi:10.11604/pamj.2019.32.124.12762 Pan Afr Med J 2019
First genetic characterisation of multidrug-resistant Mycobacterium tuberculosis isolates from Algeria. doi:10.1016/j.jgar.2019.05.010 J Glob Antimicrob Resist 2019
Using Mycobacterium tuberculosis Single-Nucleotide Polymorphisms To Predict Fluoroquinolone Treatment Response. doi:10.1128/AAC.00076-19 Antimicrob Agents Chemother 2019
Report of a Leprosy case in Singapore: an age-old disease not to be forgotten in developed countries with low-prevalence settings. doi:10.1099/acmi.0.000014 Access Microbiol 2019
Characterisation of drug resistance-associated mutations among clinical multidrug-resistant Mycobacterium tuberculosis isolates from Hebei Province, China. doi:10.1016/j.jgar.2019.03.012 J Glob Antimicrob Resist 2019
Prevalence and detection of drug resistant mutations in Mycobacterium tuberculosis among drug naïve patients in Nairobi, Kenya. doi:10.1186/s12879-019-3911-9 BMC Infect Dis 2019
A new oligonucleotide array for the detection of multidrug and extensively drug-resistance tuberculosis. doi:10.1038/s41598-019-39339-3 Sci Rep 2019
Targeting DNA Gyrase to Combat Mycobacterium tuberculosis: An Update. doi:10.2174/1568026619666190304130218 Curr Top Med Chem 2019
Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics. doi:10.1186/s13756-019-0482-x Antimicrob Resist Infect Control 2019
Robustness of the Line Probe Assay for the Rapid Diagnosis and Characterization of Mutations in Extensively Drug-Resistant Tuberculosis. doi:10.1089/mdr.2018.0268 Microb Drug Resist 2019
Application of next-generation sequencing to detect variants of drug-resistant Mycobacterium tuberculosis: genotype-phenotype correlation. doi:10.1186/s12941-018-0300-y Ann Clin Microbiol Antimicrob 2019
Pharmacophore modeling and molecular dynamics approach to identify putative DNA Gyrase B inhibitors for resistant tuberculosis. doi:10.1002/jcb.27579 J Cell Biochem 2019
Genetic Characterization of Second-Line Drug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis from the Northern Region of India. doi:10.2991/j.jegh.2018.02.100 J Epidemiol Glob Health 2018
Chemical classes targeting energy supplying GyrB domain of Mycobacterium tuberculosis. doi:10.1016/j.tube.2018.09.001 Tuberculosis (Edinb) 2018
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis. doi:10.1093/cid/ciy611 Clin Infect Dis 2018
Molecular detection of rifampin, isoniazid, and ofloxacin resistance in Iranian isolates of Mycobacterium tuberculosis by high-resolution melting analysis. doi:10.2147/IDR.S178831 Infect Drug Resist 2018
A rapid and non-pathogenic assay for association of Mycobacterium tuberculosis gyrBA mutations and fluoroquinolone resistance using recombinant Mycobacterium smegmatis. doi:10.1093/femsle/fny266 FEMS Microbiol Lett 2018
Evaluation of Genotype MTBDRplus and MTBDRsl Assays for Rapid Detection of Drug Resistance in Extensively Drug-Resistant Mycobacterium tuberculosis Isolates in Pakistan. doi:10.3389/fmicb.2018.02265 Front Microbiol 2018
Evaluation of the GenoType MTBDRplus and MTBDRsl for the detection of drug-resistant Mycobacterium tuberculosis on isolates from Beijing, China. doi:10.2147/IDR.S176609 Infect Drug Resist 2018
Rewired Downregulation of DNA Gyrase Impacts Cell Division, Expression of Topology Modulators, and Transcription in Mycobacterium smegmatis. doi:10.1016/j.jmb.2018.10.001 J Mol Biol 2018
A rapid identification technique for drug-resistant Mycobacterium tuberculosis isolates using mismatch specific cleavage enzyme. doi:10.6026/97320630014404 Bioinformation 2018
In silico designing of domain B selective gyrase inhibitors for effective treatment of resistant tuberculosis. doi:10.1016/j.tube.2018.08.005 Tuberculosis (Edinb) 2018
Whole-genome sequencing and single nucleotide polymorphisms in multidrug-resistant clinical isolates of Mycobacterium tuberculosis from the Philippines. doi:10.1016/j.jgar.2018.08.009 J Glob Antimicrob Resist 2018
Pyrosequencing: a rapid and effective sequencing method to diagnose drug-resistant tuberculosis. doi:10.1099/jmm.0.000669 J Med Microbiol 2018
Performance of an Xpert-based diagnostic algorithm for the rapid detection of drug-resistant tuberculosis among high-risk populations in a low-incidence setting. doi:10.1371/journal.pone.0200755 PLoS One 2018
Multi-center evaluation of GenoType MTBDRsl line probe assay for rapid detection of pre-XDR and XDR Mycobacterium tuberculosis in China. doi:10.1016/j.jinf.2018.06.014 J Infect 2018
Association of gyrA and rrs gene mutations detected by MTBDRsl V1 on Mycobacterium tuberculosis strains of diverse genetic background from India. doi:10.1038/s41598-018-27299-z names it Sci Rep 2018
Mutations in gyrA and gyrB in Moxifloxacin-Resistant Mycobacterium avium Complex and Mycobacterium abscessus Complex Clinical Isolates. doi:10.1128/AAC.00527-18 names it Antimicrob Agents Chemother 2018
Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015. doi:10.1016/j.cmi.2018.06.004 Clin Microbiol Infect 2018
Regulation of the gyr operon of Mycobacterium tuberculosis by overlapping promoters, DNA topology, and reiterative transcription. doi:10.1016/j.bbrc.2018.05.067 Biochem Biophys Res Commun 2018
Single-nucleotide polymorphisms related to fluoroquinolone and aminoglycoside resistance in Mycobacterium avium isolates. doi:10.2147/IDR.S160899 Infect Drug Resist 2018
Interaction between rpsL and gyrA mutations affects the fitness and dual resistance of Mycobacterium tuberculosis clinical isolates against streptomycin and fluoroquinolones. doi:10.2147/IDR.S152335 names it Infect Drug Resist 2018
Determining Genotypic Drug Resistance by Ion Semiconductor Sequencing With the Ion AmpliSeq™ TB Panel in Multidrug-Resistant Mycobacterium tuberculosis Isolates. doi:10.3343/alm.2018.38.4.316 Ann Lab Med 2018
Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study. doi:10.1016/S1473-3099(18)30073-2 Lancet Infect Dis 2018
Diagnostic accuracy of GenoType(®) MTBDRsl VER 2.0 in detecting second-line drug resistance to M. tuberculosis. doi:10.5588/ijtld.17.0663 Int J Tuberc Lung Dis 2018
Resistance to anti leprosy drugs in multi-bacillary leprosy: A cross sectional study from a tertiary care centre in eastern Uttar Pradesh, India. doi:10.4103/ijdvl.IJDVL_34_16 Indian J Dermatol Venereol Leprol 2018
Performance of Sequencing in Predicting Ofloxacin Resistance in Mycobacterium tuberculosis from Positive Bactec MGIT 960 Cultures. Ann Clin Lab Sci 2018
Multi- and Extensively Drug Resistant Mycobacterium tuberculosis in South Africa: a Molecular Analysis of Historical Isolates. doi:10.1128/JCM.01214-17 J Clin Microbiol 2018
Second-line anti-tuberculosis drug resistance testing in Ghana identifies the first extensively drug-resistant tuberculosis case. doi:10.2147/IDR.S152720 Infect Drug Resist 2018
Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15. doi:10.1016/j.cmi.2018.02.022 Clin Microbiol Infect 2018
Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco. doi:10.1186/s12879-018-3009-9 BMC Infect Dis 2018
Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii. doi:10.1128/AAC.01788-17 Antimicrob Agents Chemother 2018
Genotypic detection of fluoroquinolone resistance in drug-resistant Mycobacterium tuberculosis at a tertiary care centre in south Coastal Karnataka, India. doi:10.1016/j.jgar.2018.01.023 J Glob Antimicrob Resist 2018
Extensively drug-resistant tuberculosis in Myanmar: burden and mutations causing second-line drug resistance. doi:10.5588/ijtld.17.0321 Int J Tuberc Lung Dis 2018
Molecular drug resistance profiles of Mycobacterium tuberculosis from sputum specimens using ion semiconductor sequencing. doi:10.1016/j.mimet.2017.12.003 J Microbiol Methods 2018
Rapid Microarray-Based Detection of Rifampin, Isoniazid, and Fluoroquinolone Resistance in Mycobacterium tuberculosis by Use of a Single Cartridge. doi:10.1128/JCM.01249-17 J Clin Microbiol 2018
Detection of resistance to fluoroquinolones and injectable drugs among antituberculosis drugs by allele-specific primer extension on a microsphere-based platform. doi:10.1016/j.mimet.2017.11.007 J Microbiol Methods 2018
Molecular detection of multidrug-resistant Mycobacterium leprae from Indian leprosy patients. doi:10.1016/j.jgar.2017.10.010 J Glob Antimicrob Resist 2018
Emerging resistant clones of Mycobacterium tuberculosis in a spatiotemporal context. doi:10.1093/jac/dkx372 J Antimicrob Chemother 2018
In Vitro Activity and MIC of Sitafloxacin against Multidrug-Resistant and Extensively Drug-Resistant Mycobacterium tuberculosis Isolated in Thailand. doi:10.1128/AAC.00825-17 Antimicrob Agents Chemother 2018
Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco. doi:10.1016/j.jgar.2017.10.003 names it J Glob Antimicrob Resist 2018
Activity of 2-(quinolin-4-yloxy)acetamides in Mycobacterium tuberculosis clinical isolates and identification of their molecular target by whole-genome sequencing. doi:10.1016/j.ijantimicag.2017.08.023 Int J Antimicrob Agents 2018
Characterization of Ofloxacin Interaction with Mutated (A91V) Quinolone Resistance Determining Region of DNA Gyrase in Mycobacterium Leprae through Computational Simulation. doi:10.1007/s12013-017-0822-5 Cell Biochem Biophys 2018
Molecular detection of drug resistance to ofloxacin and kanamycin in Mycobacterium tuberculosis by using multiplex allele-specific PCR. doi:10.1016/j.jiph.2017.03.007 J Infect Public Health 2018
Molecular characteristics of ofloxacin mono-resistant Mycobacterium tuberculosis isolates from new and previously treated tuberculosis patients. doi:10.1002/jcla.22202 J Clin Lab Anal 2018
Natural environmental water sources in endemic regions of northeastern Brazil are potential reservoirs of viable Mycobacterium leprae. doi:10.1590/0074-02760170117 Mem Inst Oswaldo Cruz 2017
Mutation analysis for detection of drug resistance in mycobacterium tuberculosis isolates from Khyber Pakhtunkhwa, Pakistan. J Pak Med Assoc 2017
Applied multiplex allele specific PCR to detect second-line drug resistance among multidrug-resistant tuberculosis in China. doi:10.1016/j.tube.2017.07.010 Tuberculosis (Edinb) 2017
Fluoroquinolone Resistance Mutation Detection Is Equivalent to Culture-Based Drug Sensitivity Testing for Predicting Multidrug-Resistant Tuberculosis Treatment Outcome: A Retrospective Cohort Study. doi:10.1093/cid/cix556 Clin Infect Dis 2017
Whole-genome sequencing illuminates the evolution and spread of multidrug-resistant tuberculosis in Southwest Nigeria. doi:10.1371/journal.pone.0184510 PLoS One 2017
Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis. doi:10.1056/NEJMoa1614915 N Engl J Med 2017
[The Spectrum of Mutations in Genes Associated with Resistance to Rifampicin, Isoniazid, and Fluoroquinolones in the Clinical Strains of M. tuberculosis Reflects the Transmissibility of Mutant Clones]. doi:10.7868/S0026898417030041 Mol Biol (Mosk) 2017
Mycobacterium tuberculosis Subculture Results in Loss of Potentially Clinically Relevant Heteroresistance. doi:10.1128/AAC.00888-17 Antimicrob Agents Chemother 2017
Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China. doi:10.1155/2017/4563826 Biomed Res Int 2017
In Silico Prediction of Antibiotic Resistance in Mycobacterium ulcerans Agy99 through Whole Genome Sequence Analysis. doi:10.4269/ajtmh.16-0478 Am J Trop Med Hyg 2017
In Vitro Drug Susceptibility of Bedaquiline, Delamanid, Linezolid, Clofazimine, Moxifloxacin, and Gatifloxacin against Extensively Drug-Resistant Tuberculosis in Beijing, China. doi:10.1128/AAC.00900-17 Antimicrob Agents Chemother 2017
A comparative study of phenotypic and genotypic first- and second-line drug resistance testing of Mycobacterium tuberculosis. doi:10.1016/j.biologicals.2017.07.003 Biologicals 2017
High incidence of fluoroquinolone resistance and effect of efflux pump inhibitors on moxifloxacin resistance among Mycobacterium tuberculosis isolates causing urinary tract infection in Taiwan. doi:10.1016/j.ijantimicag.2017.04.010 Int J Antimicrob Agents 2017
Impact of gyrB and eis Mutations in Improving Detection of Second-Line-Drug Resistance among Mycobacterium tuberculosis Isolates from Georgia. doi:10.1128/AAC.01921-16 Antimicrob Agents Chemother 2017
In vitro activity of sitafloxacin against Mycobacterium tuberculosis with gyrA/B mutations isolated in Japan. doi:10.1099/jmm.0.000493 names it J Med Microbiol 2017
qPCR-High resolution melt analysis for drug susceptibility testing of Mycobacterium leprae directly from clinical specimens of leprosy patients. doi:10.1371/journal.pntd.0005506 PLoS Negl Trop Dis 2017
Prevalence and extent of heteroresistance by next generation sequencing of multidrug-resistant tuberculosis. doi:10.1371/journal.pone.0176522 PLoS One 2017
Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis? doi:10.1093/jac/dkx150 J Antimicrob Chemother 2017
Diagnostic performance of Anyplex II MTB/MDR/XDR for detection of resistance to first and second line drugs in Mycobacterium tuberculosis. doi:10.1016/j.mimet.2017.05.006 J Microbiol Methods 2017
First Insight Into the Fluoroquinolone and Aminoglycoside Resistance of Multidrug-Resistant Mycobacterium tuberculosis in Saudi Arabia. doi:10.4269/ajtmh.16-0579 Am J Trop Med Hyg 2017
Performance of TaqMan array card to detect TB drug resistance on direct specimens. doi:10.1371/journal.pone.0177167 PLoS One 2017
Expression, purification, and characterization of recombinant 8 kDa gelsolin fragment. doi:10.1016/j.pep.2017.04.016 Protein Expr Purif 2017
Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing. doi:10.1186/s12879-017-2409-6 BMC Infect Dis 2017
Increased Tuberculosis Patient Mortality Associated with Mycobacterium tuberculosis Mutations Conferring Resistance to Second-Line Antituberculous Drugs. doi:10.1128/JCM.00152-17 J Clin Microbiol 2017
Double mutation in DNA gyrase confers moxifloxacin resistance and decreased fitness of Mycobacterium smegmatis. doi:10.1093/jac/dkx110 J Antimicrob Chemother 2017
Double Mutants in DNA Gyrase Lead to Ofloxacin Resistance in Mycobacterium tuberculosis. doi:10.1002/jcb.25954 J Cell Biochem 2017
Antituberculosis Drug Resistance in Pulmonary Isolates of Mycobacterium tuberculosis, Cuba 2012-2014. doi:10.37757/MR2017.V19.N1.3 MEDICC Rev 2017
Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria. doi:10.1128/AAC.02100-16 Antimicrob Agents Chemother 2017
Some Synonymous and Nonsynonymous gyrA Mutations in Mycobacterium tuberculosis Lead to Systematic False-Positive Fluoroquinolone Resistance Results with the Hain GenoType MTBDRsl Assays. doi:10.1128/AAC.02169-16 names it Antimicrob Agents Chemother 2017
FIND Tuberculosis Strain Bank: a Resource for Researchers and Developers Working on Tests To Detect Mycobacterium tuberculosis and Related Drug Resistance. doi:10.1128/JCM.01662-16 J Clin Microbiol 2017
Assessment of a 96-Well Plate Assay of Quantitative Drug Susceptibility Testing for Mycobacterium Tuberculosis Complex in China. doi:10.1371/journal.pone.0169413 PLoS One 2017
pncA mutations are associated with slower sputum conversion during standard treatment of multidrug-resistant tuberculosis. doi:10.1016/j.ijantimicag.2016.10.012 Int J Antimicrob Agents 2017
Evaluation of the GenoType MTBDRsl Version 2.0 Assay for Second-Line Drug Resistance Detection of Mycobacterium tuberculosis Isolates in South Africa. doi:10.1128/JCM.01865-16 J Clin Microbiol 2017
De Novo Emergence of Genetically Resistant Mutants of Mycobacterium tuberculosis from the Persistence Phase Cells Formed against Antituberculosis Drugs In Vitro. doi:10.1128/AAC.01343-16 Antimicrob Agents Chemother 2017
Detection of Isoniazid-, Fluoroquinolone-, Amikacin-, and Kanamycin-Resistant Tuberculosis in an Automated, Multiplexed 10-Color Assay Suitable for Point-of-Care Use. doi:10.1128/JCM.01771-16 J Clin Microbiol 2017
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from high prevalence tuberculosis states in Mexico. doi:10.1016/j.meegid.2016.09.012 Infect Genet Evol 2017
Insights into Pyrazinamidase and DNA Gyrase Protein Structures in Resistant and Susceptible Clinical Isolates of Mycobacterium tuberculosis. Tanaffos 2016
Impact of genotypic and phenotypic resistance to second-line anti-tuberculosis drugs on treatment outcomes in multidrug-resistant tuberculosis in China. doi:10.1016/j.ijmyco.2016.11.007 Int J Mycobacteriol 2016
Molecular drug susceptibility testing against the first-line (rifampin and isoniazid) and second-line (ciprofloxacin-amikacin and kanamycin) treatment in different subtypes of Mycobacterium simiae. doi:10.1016/j.ijmyco.2016.11.006 Int J Mycobacteriol 2016
A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, Russia. doi:10.1371/journal.pone.0167093 PLoS One 2016
Molecular detection of fluoroquinolone resistance-associated gyrA mutations in ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Iran and Belarus. doi:10.1016/j.ijmyco.2016.07.004 names it Int J Mycobacteriol 2016
Performance of the GenoType MTBDRplus assay (v2.0) and a new extended GenoType MTBDRsl assay (v2.0) for the molecular detection of multi- and extensively drug-resistant Mycobacterium tuberculosis on isolates primarily from Lithuania. doi:10.1016/j.diagmicrobio.2016.08.026 Diagn Microbiol Infect Dis 2016
Mutations in the drug resistance-determining region of Mycobacterium lepromatosis isolated from leprosy patients in Mexico. doi:10.1111/1346-8138.13483 J Dermatol 2016
Leprosy Drug Resistance Surveillance in Colombia: The Experience of a Sentinel Country. doi:10.1371/journal.pntd.0005041 PLoS Negl Trop Dis 2016
In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests. doi:10.1093/jac/dkw344 J Antimicrob Chemother 2016
A Case of Fluoroquinolone-Resistant Leprosy Discovered after 9 Years of Misdiagnosis. doi:10.1155/2016/4632369 Case Rep Infect Dis 2016
Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis. doi:10.1186/s12879-016-1781-y BMC Infect Dis 2016
Genomic Analysis of the Evolution of Fluoroquinolone Resistance in Mycobacterium tuberculosis Prior to Tuberculosis Diagnosis. doi:10.1128/AAC.00664-16 Antimicrob Agents Chemother 2016
Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India. doi:10.1128/JCM.00670-16 names it J Clin Microbiol 2016
Wild-Type and Non-Wild-Type Mycobacterium tuberculosis MIC Distributions for the Novel Fluoroquinolone Antofloxacin Compared with Those for Ofloxacin, Levofloxacin, and Moxifloxacin. doi:10.1128/AAC.00393-16 Antimicrob Agents Chemother 2016
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates. doi:10.1128/AAC.00539-16 Antimicrob Agents Chemother 2016
Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis. doi:10.1093/jac/dkw169 names it J Antimicrob Chemother 2016
Analysis of DNA gyrA Gene Mutation in Clinical and Environmental Ciprofloxacin-Resistant Isolates of Non-Tuberculous Mycobacteria Using Molecular Methods. doi:10.5812/jjm.30018 names it Jundishapur J Microbiol 2016
Moxifloxacin Improves Treatment Outcomes in Patients with Ofloxacin-Resistant Multidrug-Resistant Tuberculosis. doi:10.1128/AAC.00425-16 Antimicrob Agents Chemother 2016
Clinical Features and Drug-Resistance Profile of Urinary Tuberculosis in South-Western China: A Cross-sectional Study. doi:10.1097/MD.0000000000003537 Medicine (Baltimore) 2016
Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape. doi:10.1128/AAC.00222-16 Antimicrob Agents Chemother 2016
Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains. doi:10.1128/JCM.00051-16 J Clin Microbiol 2016
Simultaneous drug resistance detection and genotyping of Mycobacterium tuberculosis using a low-density hydrogel microarray. doi:10.1093/jac/dkw015 J Antimicrob Chemother 2016
Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni. doi:10.1002/dta.1937 Drug Test Anal 2016
Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis. doi:10.1093/jac/dkv499 J Antimicrob Chemother 2016
A molecular platform for the diagnosis of multidrug-resistant and pre-extensively drug-resistant tuberculosis based on single nucleotide polymorphism mutations present in Colombian isolates of Mycobacterium tuberculosis. doi:10.1590/0074-02760150306 Mem Inst Oswaldo Cruz 2016
Molecular Analysis of Sarcoidosis Granulomas Reveals Antimicrobial Targets. doi:10.1165/rcmb.2015-0212OC Am J Respir Cell Mol Biol 2016
Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase. doi:10.1073/pnas.1525055113 Proc Natl Acad Sci U S A 2016
Mutations in gyrA and gyrB among Fluoroquinolone- and Multidrug-Resistant Mycobacterium tuberculosis Isolates. doi:10.1128/AAC.01049-15 names it Antimicrob Agents Chemother 2016
Gyrase Mutations Are Associated with Variable Levels of Fluoroquinolone Resistance in Mycobacterium tuberculosis. doi:10.1128/JCM.02775-15 J Clin Microbiol 2016
Subspecies distribution and macrolide and fluoroquinolone resistance genetics of Mycobacterium abscessus in Korea. doi:10.5588/ijtld.15.0068 Int J Tuberc Lung Dis 2016
Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESIST-TB consensus statement. doi:10.5588/ijtld.15.0221 Int J Tuberc Lung Dis 2016
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors. doi:10.1016/j.bmc.2015.11.039 Bioorg Med Chem 2016
Specific gyrA gene mutations predict poor treatment outcome in MDR-TB. doi:10.1093/jac/dkv360 names it J Antimicrob Chemother 2016
Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB. doi:10.1093/jac/dkv353 names it J Antimicrob Chemother 2016
Prevalence of mutations conferring resistance among multi- and extensively drug-resistant Mycobacterium tuberculosis isolates in China. doi:10.1038/ja.2015.106 J Antibiot (Tokyo) 2016
Engineering versatile protein expression systems mediated by inteins in Escherichia coli. doi:10.1007/s00253-015-6960-z Appl Microbiol Biotechnol 2016
Second-line anti-tuberculosis drug resistance and its genetic determinants in multidrug-resistant Mycobacterium tuberculosis clinical isolates. doi:10.1016/j.jmii.2015.04.003 J Microbiol Immunol Infect 2016
[Detection of mutations in the gyrA and gyrB genes associated with fluoroquinolone-resistance among clinical isolates of Mycobacterium abscessus in China]. names it Zhonghua Jie He He Hu Xi Za Zhi 2015
Genome sequence comparisons of serial multi-drug-resistant Mycobacterium tuberculosis isolates over 21 years of infection in a single patient. doi:10.1099/mgen.0.000037 Microb Genom 2015
Determination of MICs of levofloxacin for Mycobacterium tuberculosis with gyrA mutations. doi:10.5588/ijtld.14.0277 names it Int J Tuberc Lung Dis 2015
Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal. doi:10.1371/journal.pmed.1001880 PLoS Med 2015
Identification of chebulinic acid as potent natural inhibitor of M. tuberculosis DNA gyrase and molecular insights into its binding mode of action. doi:10.1016/j.compbiolchem.2015.09.006 Comput Biol Chem 2015
Pyrosequencing for rapid detection of Mycobacterium tuberculosis second-line drugs and ethambutol resistance. doi:10.1016/j.diagmicrobio.2015.07.004 Diagn Microbiol Infect Dis 2015
Proteomic analysis of ofloxacin-mono resistant Mycobacterium tuberculosis isolates. doi:10.1016/j.jprot.2015.07.031 J Proteomics 2015
Correlation between GyrA substitutions and ofloxacin, levofloxacin, and moxifloxacin cross-resistance in Mycobacterium tuberculosis. doi:10.1128/AAC.00662-15 names it Antimicrob Agents Chemother 2015
Drug resistance in Mycobacterium leprae from patients with leprosy in China. doi:10.1111/ced.12665 Clin Exp Dermatol 2015
Comparative Evaluation of Sloppy Molecular Beacon and Dual-Labeled Probe Melting Temperature Assays to Identify Mutations in Mycobacterium tuberculosis Resulting in Rifampin, Fluoroquinolone and Aminoglycoside Resistance. doi:10.1371/journal.pone.0126257 PLoS One 2015
Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review. doi:10.1371/journal.pone.0120470 names it PLoS One 2015
Fluoroquinolones for the treatment of tuberculosis in children. doi:10.1016/j.tube.2015.02.037 Tuberculosis (Edinb) 2015
Whole genome sequencing based characterization of extensively drug-resistant Mycobacterium tuberculosis isolates from Pakistan. doi:10.1371/journal.pone.0117771 PLoS One 2015
Integrated microfluidic card with TaqMan probes and high-resolution melt analysis to detect tuberculosis drug resistance mutations across 10 genes. doi:10.1128/mBio.02273-14 mBio 2015
Low resistance to first and second line anti-tuberculosis drugs among treatment naive pulmonary tuberculosis patients in southwestern Uganda. doi:10.1371/journal.pone.0118191 PLoS One 2015
Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis. doi:10.1128/AAC.04058-14 Antimicrob Agents Chemother 2015
Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutations using the genotype MTBDRsl assay. doi:10.1016/j.tube.2014.11.003 names it Tuberculosis (Edinb) 2015
Comparative analysis of the effectiveness of C-terminal cleavage intein-based constructs in producing a recombinant analog of anophelin, an anticoagulant from Anopheles albimanus. doi:10.1007/s12010-014-1400-6 Appl Biochem Biotechnol 2015
Molecular characterisation of extensively drug-resistant Mycobacterium tuberculosis isolates in China. doi:10.1016/j.ijantimicag.2014.09.018 Int J Antimicrob Agents 2015
Evaluation of pyrosequencing for detecting extensively drug-resistant Mycobacterium tuberculosis among clinical isolates from four high-burden countries. doi:10.1128/AAC.03614-14 Antimicrob Agents Chemother 2015
Assays, surrogates, and alternative technologies for a TB lead identification program targeting DNA gyrase ATPase. doi:10.1177/1087057114554170 J Biomol Screen 2015
Prevalence of gyrA and B gene mutations in fluoroquinolone-resistant and -sensitive clinical isolates of Mycobacterium tuberculosis and their relationship with MIC of ofloxacin. doi:10.1038/ja.2014.95 names it J Antibiot (Tokyo) 2015
The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis. doi:10.1128/microbiolspec.MGM2-0009-2013 Microbiol Spectr 2014
[Analysis of genetic determinants of multidrug and extensively drug-resistant Mycobacterium tuberculosis using oligonucleotide microchip]. Mol Biol (Mosk) 2014
[Resistance to second-line anti-tuberculosis drugs among peruvian multidrug resistant Mycobacterium tuberculosis strains]. Rev Peru Med Exp Salud Publica 2014
[Conventional and molecular diagnosis in a group of patients with drug-resistant tuberculosis]. Pneumologia 2014
Identification of primary drug resistance to rifampin in Mycobacterium leprae strains from leprosy patients in Amazonas State, Brazil. doi:10.1128/JCM.01688-14 J Clin Microbiol 2014
Quinolone-containing therapies in the eradication of Helicobacter pylori. doi:10.1155/2014/151543 Biomed Res Int 2014
Moxifloxacin resistance in the F15/LAM4/KZN extensively drug-resistant strain of Mycobacterium tuberculosis. doi:10.2147/IDR.S65417 Infect Drug Resist 2014
Characterization of extensively drug-resistant Mycobacterium tuberculosis isolates circulating in Siberia. doi:10.1186/1471-2334-14-478 BMC Infect Dis 2014
[Rapid detection of mutations related to Mycobacterium leprae drug resistance by using Hp-rPCR (hairpin primer- real time PCR) method]. doi:10.5025/hansen.83.6 Nihon Hansenbyo Gakkai Zasshi 2014
Rapid molecular screening for multidrug-resistant tuberculosis in a resource-limited region of China. doi:10.1111/tmi.12359 Trop Med Int Health 2014
[Heteroresistance in Mycobacteria tuberculosis is an important factor for the inconsistency between the results of phenotype and genotype drug susceptibility tests]. Zhonghua Jie He He Hu Xi Za Zhi 2014
[Induction in vitro and stability of Mycobacterium tuberculosis resistance to ofloxacin]. Zhonghua Yu Fang Yi Xue Za Zhi 2014
Ofloxacin resistance in Mycobacterium tuberculosis is associated with efflux pump activity independent of resistance pattern and genotype. doi:10.1089/mdr.2013.0171 Microb Drug Resist 2014
Pseudo-outbreak of pre-extensively drug-resistant (Pre-XDR) tuberculosis in Kinshasa: collateral damage caused by false detection of fluoroquinolone resistance by GenoType MTBDRsl. doi:10.1128/JCM.00398-14 J Clin Microbiol 2014
Mechanisms of fluoroquinolone monoresistance in Mycobacterium tuberculosis. doi:10.1111/1574-6968.12401 FEMS Microbiol Lett 2014
Prediction of XDR/pre-XDR tuberculosis by genetic mutations among MDR cases from a hospital in Shandong, China. doi:10.1016/j.tube.2014.03.005 Tuberculosis (Edinb) 2014
First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA. doi:10.1371/journal.pone.0095083 names it PLoS One 2014
Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China. doi:10.1128/AAC.02426-14 Antimicrob Agents Chemother 2014
MUBII-TB-DB: a database of mutations associated with antibiotic resistance in Mycobacterium tuberculosis. doi:10.1186/1471-2105-15-107 BMC Bioinformatics 2014
Pyrosequencing for rapid detection of tuberculosis resistance in clinical isolates and sputum samples from re-treatment pulmonary tuberculosis patients. doi:10.1186/1471-2334-14-200 BMC Infect Dis 2014
High proportion of heteroresistance in gyrA and gyrB in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. doi:10.1128/AAC.02066-13 names it Antimicrob Agents Chemother 2014
Association of gyrA/B mutations and resistance levels to fluoroquinolones in clinical isolates of Mycobacterium tuberculosis. doi:10.1038/emi.2014.21 names it Emerg Microbes Infect 2014
Molecular characterization of Mycobacterium tuberculosis isolates from elephants of Nepal. doi:10.1016/j.tube.2013.12.008 Tuberculosis (Edinb) 2014
Moxifloxacin retains antimycobacterial activity in the presence of gyrA mutations. doi:10.1128/AAC.02583-13 names it Antimicrob Agents Chemother 2014
Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding. doi:10.1074/jbc.M113.529164 J Biol Chem 2014
Molecular basis for the differential quinolone susceptibility of mycobacterial DNA gyrase. doi:10.1128/AAC.01958-13 Antimicrob Agents Chemother 2014
Molecular characterization of multidrug-resistant Mycobacterium tuberculosis isolates from China. doi:10.1128/AAC.01792-13 Antimicrob Agents Chemother 2014
Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. doi:10.1128/JCM.02701-13 J Clin Microbiol 2014
Prevalence and molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates in China. doi:10.1128/AAC.01228-13 Antimicrob Agents Chemother 2014
Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. doi:10.1093/jac/dkt358 J Antimicrob Chemother 2014
Geographical differences associated with single-nucleotide polymorphisms (SNPs) in nine gene targets among resistant clinical isolates of Mycobacterium tuberculosis. doi:10.1128/JCM.00857-13 J Clin Microbiol 2014
Inhibition of the Mycobacterium tuberculosis reserpine-sensitive efflux pump augments intracellular concentrations of ciprofloxacin and enhances susceptibility of some clinical isolates. doi:10.1016/j.jfma.2012.03.009 J Formos Med Assoc 2013
Resistance of M. leprae to quinolones: a question of relativity? doi:10.1371/journal.pntd.0002559 PLoS Negl Trop Dis 2013
Application of quantitative second-line drug susceptibility testing at a multidrug-resistant tuberculosis hospital in Tanzania. doi:10.1186/1471-2334-13-432 BMC Infect Dis 2013
Rapid detection of drug resistance and mutational patterns of extensively drug-resistant strains by a novel GenoType® MTBDRsl assay. doi:10.4103/0022-3859.118034 J Postgrad Med 2013
Detection of streptomycin and quinolone resistance in Mycobacterium tuberculosis by a low-density DNA array. doi:10.1016/j.tube.2013.07.001 Tuberculosis (Edinb) 2013
Mycobacterium tuberculosis DNA gyrase possesses two functional GyrA-boxes. doi:10.1042/BJ20130430 names it Biochem J 2013
Identification of the likely translational start of Mycobacterium tuberculosis GyrB. doi:10.1186/1756-0500-6-274 BMC Res Notes 2013
Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis. doi:10.1128/AAC.00506-13 Antimicrob Agents Chemother 2013
Molecular and phenotypic characterisation of Mycobacterium tuberculosis resistant to anti-tuberculosis drugs. doi:10.5588/ijtld.12.0949 Int J Tuberc Lung Dis 2013
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones. doi:10.1016/j.ijantimicag.2013.04.027 Int J Antimicrob Agents 2013
Determination of critical concentrations of moxifloxacin and gatifloxacin for drug susceptibility testing of Mycobacterium tuberculosis in the BACTEC MGIT 960 system. doi:10.1093/jac/dkt202 J Antimicrob Chemother 2013
Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China. doi:10.1128/AAC.00102-13 Antimicrob Agents Chemother 2013
Detection of second-line drug resistance in Mycobacterium tuberculosis using oligonucleotide microarrays. doi:10.1186/1471-2334-13-240 BMC Infect Dis 2013
Clinical isolates of Mycobacterium abscessus in Guangzhou area most possibly from the environmental infection showed variable susceptibility. Chin Med J (Engl) 2013
Predictive value of molecular drug resistance testing of Mycobacterium tuberculosis isolates in Valle del Cauca, Colombia. doi:10.1128/JCM.00429-13 J Clin Microbiol 2013
Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea. doi:10.1016/j.diagmicrobio.2013.02.035 Diagn Microbiol Infect Dis 2013
Characterization of multiple and extensively drug resistant Mycobacterium tuberculosis isolates with different ofloxacin-resistance levels. doi:10.1016/j.tube.2013.02.005 Tuberculosis (Edinb) 2013
Digital PCR to detect and quantify heteroresistance in drug resistant Mycobacterium tuberculosis. doi:10.1371/journal.pone.0057238 PLoS One 2013
Mycobacterium leprae in Colombia described by SNP7614 in gyrA, two minisatellites and geography. doi:10.1016/j.meegid.2012.12.015 names it Infect Genet Evol 2013
Triplex real-time PCR melting curve analysis for detecting Mycobacterium tuberculosis mutations associated with resistance to second-line drugs in a single reaction. doi:10.1093/jac/dks509 J Antimicrob Chemother 2013
Characterization of extensively drug-resistant Mycobacterium tuberculosis in Nepal. doi:10.1016/j.tube.2012.10.007 Tuberculosis (Edinb) 2013
From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: the stepwise mode of resistance acquisition. doi:10.1093/jac/dks371 J Antimicrob Chemother 2013
Analysis of mutations in the gyrA and gyrB genes and their association with the resistance of Mycobacterium tuberculosis to levofloxacin, moxifloxacin and gatifloxacin. doi:10.1099/jmm.0.046821-0 names it J Med Microbiol 2013
[Evaluation of GenoType MTBDRsl for testing resistance of Mycobacterium tuberculosis isolates to fluoroquinlone, aminoglycoside, and ethambutol]. Kekkaku 2012
Rapid identification of extensively and extremely drug resistant tuberculosis from multidrug resistant strains; using PCR-RFLP and PCR-SSCP. Iran J Microbiol 2012
Impact of amino acid substitutions in B subunit of DNA gyrase in Mycobacterium leprae on fluoroquinolone resistance. doi:10.1371/journal.pntd.0001838 PLoS Negl Trop Dis 2012
Heterogeneity of Mycobacterium tuberculosis strains in Makassar, Indonesia. doi:10.5588/ijtld.12.0055 Int J Tuberc Lung Dis 2012
Binding of two DNA molecules by type II topoisomerases for decatenation. doi:10.1093/nar/gks843 Nucleic Acids Res 2012
Next-generation ion torrent sequencing of drug resistance mutations in Mycobacterium tuberculosis strains. doi:10.1128/JCM.01893-12 J Clin Microbiol 2012
Drug resistance-related mutations in multidrug-resistant Mycobacterium tuberculosis isolates from diverse geographical regions. doi:10.1016/j.ijmyco.2012.08.001 Int J Mycobacteriol 2012
Detection of antibiotic resistance in leprosy using GenoType LepraeDR, a novel ready-to-use molecular test. doi:10.1371/journal.pntd.0001739 PLoS Negl Trop Dis 2012
The role of Ca²⁺ in the activity of Mycobacterium tuberculosis DNA gyrase. doi:10.1093/nar/gks704 Nucleic Acids Res 2012
New insights into fluoroquinolone resistance in Mycobacterium tuberculosis: functional genetic analysis of gyrA and gyrB mutations. doi:10.1371/journal.pone.0039754 names it PLoS One 2012
'Z(S)-MDR-TB' versus 'Z(R)-MDR-TB': improving treatment of MDR-TB by identifying pyrazinamide susceptibility. doi:10.1038/emi.2012.18 Emerg Microbes Infect 2012
Molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates from Shanghai, China. doi:10.1016/j.diagmicrobio.2012.03.025 Diagn Microbiol Infect Dis 2012
Molecular characterization of multidrug- and extensively drug-resistant Mycobacterium tuberculosis strains in Jiangxi, China. doi:10.1128/JCM.06860-11 J Clin Microbiol 2012
Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. doi:10.1016/s1413-8670(12)70294-5 names it Braz J Infect Dis 2012
gyrA/B fluoroquinolone resistance allele profiles amongst Mycobacterium tuberculosis isolates from mainland China. doi:10.1016/j.ijantimicag.2012.02.015 names it Int J Antimicrob Agents 2012
Low rates of synonymous mutations in sequences of Mycobacterium tuberculosis GyrA and KatG genes. doi:10.1016/j.tube.2012.03.004 names it Tuberculosis (Edinb) 2012
Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients. doi:10.1128/JCM.06561-11 J Clin Microbiol 2012
Detection of first- and second-line drug resistance in Mycobacterium tuberculosis clinical isolates by pyrosequencing. doi:10.1128/JCM.06664-11 J Clin Microbiol 2012
Mechanisms for defining supercoiling set point of DNA gyrase orthologs: II. The shape of the GyrA subunit C-terminal domain (CTD) is not a sole determinant for controlling supercoiling efficiency. doi:10.1074/jbc.M112.345736 names it J Biol Chem 2012
Sensitivities of ciprofloxacin-resistant Mycobacterium tuberculosis clinical isolates to fluoroquinolones: role of mutant DNA gyrase subunits in drug resistance. doi:10.1016/j.ijantimicag.2012.01.007 Int J Antimicrob Agents 2012
High-resolution melting analysis for the rapid detection of fluoroquinolone and streptomycin resistance in Mycobacterium tuberculosis. doi:10.1371/journal.pone.0031934 PLoS One 2012
gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. doi:10.1093/jac/dks033 names it J Antimicrob Chemother 2012
Multiplex allele specific PCR for rapid detection of extensively drug resistant tuberculosis. doi:10.1016/j.tube.2012.01.004 Tuberculosis (Edinb) 2012
Mycobacterium tuberculosis population structure determines the outcome of genetics-based second-line drug resistance testing. doi:10.1128/AAC.05905-11 Antimicrob Agents Chemother 2012
Extending the definition of the GyrB quinolone resistance-determining region in Mycobacterium tuberculosis DNA gyrase for assessing fluoroquinolone resistance in M. tuberculosis. doi:10.1128/AAC.06272-11 Antimicrob Agents Chemother 2012
A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. doi:10.1093/jac/dkr566 J Antimicrob Chemother 2012
Influence of lineage-specific amino acid dimorphisms in GyrA on Mycobacterium tuberculosis resistance to fluoroquinolones. names it Jpn J Infect Dis 2012
Evaluation of the GenoType® MTBDRsl assay for susceptibility testing of second-line anti-tuberculosis drugs. doi:10.5588/ijtld.10.0600 Int J Tuberc Lung Dis 2012
The TDR Tuberculosis Strain Bank: a resource for basic science, tool development and diagnostic services. doi:10.5588/ijtld.11.0223 Int J Tuberc Lung Dis 2012
High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility. doi:10.1128/JCM.05286-11 names it J Clin Microbiol 2012
Real-time PCR and high-resolution melt analysis for rapid detection of Mycobacterium leprae drug resistance mutations and strain types. doi:10.1128/JCM.05183-11 J Clin Microbiol 2012
Multiplex allele-specific PCR combined with PCR-RFLP analysis for rapid detection of gyrA gene fluoroquinolone resistance mutations in Mycobacterium tuberculosis. doi:10.1016/j.mimet.2011.10.015 names it J Microbiol Methods 2012
Amino acid substitutions at position 95 in GyrA can add fluoroquinolone resistance to Mycobacterium leprae. doi:10.1128/AAC.05890-11 names it Antimicrob Agents Chemother 2012
Evaluation of gyrase B as a drug target in Mycobacterium tuberculosis. doi:10.1093/jac/dkr449 J Antimicrob Chemother 2012
Phenotypic and molecular characterization of quinolone resistance in Mycobacterium abscessus subsp. bolletii recovered from postsurgical infections. doi:10.1099/jmm.0.034942-0 J Med Microbiol 2012
gyrA and gyrB gene mutation in ciprofloxacin-resistant Mycobacterium massiliense clinical isolates from Southern Brazil. doi:10.1089/mdr.2011.0047 names it Microb Drug Resist 2012
gyrA and gyrB mutations in ofloxacin-resistant Mycobacterium tuberculosis clinical isolates in Thailand. names it Southeast Asian J Trop Med Public Health 2011
Docking studies on novel analogues of 8 methoxy fluoroquinolones against GyrA mutants of Mycobacterium tuberculosis. doi:10.1186/1472-6807-11-47 names it BMC Struct Biol 2011
Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes. doi:10.1186/1471-2334-11-255 BMC Infect Dis 2011
Characterization of mutations conferring extensive drug resistance to Mycobacterium tuberculosis isolates in Pakistan. doi:10.1128/AAC.05101-11 Antimicrob Agents Chemother 2011
Rapid detection of isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis clinical isolates using high-resolution melting analysis. doi:10.1128/JCM.01068-11 J Clin Microbiol 2011
DNA gyrase inhibition assays are necessary to demonstrate fluoroquinolone resistance secondary to gyrB mutations in Mycobacterium tuberculosis. doi:10.1128/AAC.00707-11 Antimicrob Agents Chemother 2011
The dimer state of GyrB is an active form: implications for the initial complex assembly and processive strand passage. doi:10.1093/nar/gkr553 Nucleic Acids Res 2011
Survival of civilian and prisoner drug-sensitive, multi- and extensive drug- resistant tuberculosis cohorts prospectively followed in Russia. doi:10.1371/journal.pone.0020531 PLoS One 2011
Extending the scope of site-specific cysteine bioconjugation by appending a prelabeled cysteine tag to proteins using protein trans-splicing. doi:10.1007/978-1-61779-151-2_9 Methods Mol Biol 2011
Incidence of moxifloxacin resistance in clinical Mycobacterium tuberculosis isolates in Houston, Texas. doi:10.1128/JCM.00231-11 J Clin Microbiol 2011
Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance. doi:10.1128/AAC.00042-11 Antimicrob Agents Chemother 2011
Detection of mutations in folp1, rpoB and gyrA genes of M. leprae by PCR- direct sequencing--a rapid tool for screening drug resistance in leprosy. names it Lepr Rev 2011
Evaluation of two molecular assays for rapid detection of mycobacterium tuberculosis resistance to fluoroquinolones in high-tuberculosis and -multidrug-resistance Settings. doi:10.1128/JCM.01889-10 J Clin Microbiol 2011
Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates. Indian J Med Res 2011
Genotyping of Mycobacterium leprae from Brazilian leprosy patients suggests the occurrence of reinfection or of bacterial population shift during disease relapse. doi:10.1099/jmm.0.029389-0 J Med Microbiol 2011
Performance assessment of the GenoType MTBDRsl test and DNA sequencing for detection of second-line and ethambutol drug resistance among patients infected with multidrug-resistant Mycobacterium tuberculosis. doi:10.1128/JCM.00197-11 J Clin Microbiol 2011
Characteristic resistance mechanism of Mycobacterium tuberculosis to DC-159a, a new respiratory quinolone. doi:10.1128/AAC.00417-10 Antimicrob Agents Chemother 2011
First report of molecular detection of fluoroquinolone resistance-associated gyrA mutations in multidrug-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. doi:10.1186/1756-0500-4-123 names it BMC Res Notes 2011
Population-based investigation of fluoroquinolones resistant tuberculosis in rural eastern China. doi:10.1016/j.tube.2011.03.001 Tuberculosis (Edinb) 2011
Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. doi:10.1186/1471-2334-11-78 names it BMC Infect Dis 2011
Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. doi:10.1128/AAC.00033-11 Antimicrob Agents Chemother 2011
Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. doi:10.1128/AAC.01550-10 Antimicrob Agents Chemother 2011
Analysis of drug-resistant strains of Mycobacterium leprae in an endemic area of Vietnam. doi:10.1093/cid/ciq217 Clin Infect Dis 2011
Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: report from a tertiary care center in India. doi:10.1128/JCM.00113-11 J Clin Microbiol 2011
Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community. Int J Tuberc Lung Dis 2011
Isolation and characterization of "Pseudomonas andersonii" from four cases of pulmonary granulomas and emended species description. doi:10.1128/JCM.02219-10 J Clin Microbiol 2011
Rapid detection of fluoroquinolone-resistant and heteroresistant Mycobacterium tuberculosis by use of sloppy molecular beacons and dual melting-temperature codes in a real-time PCR assay. doi:10.1128/JCM.02271-10 J Clin Microbiol 2011
Evaluation of a line probe assay for the rapid detection of gyrA mutations associated with fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis. doi:10.1099/jmm.0.024729-0 names it J Med Microbiol 2011
Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: functional analysis of gyrA mutation at position 74. doi:10.1128/AAC.00920-10 names it Antimicrob Agents Chemother 2011
Possible mode of emergence for drug-resistant leprosy is revealed by an analysis of samples from Mexico. Jpn J Infect Dis 2010
[The effects of gene mutation related to drug resistance and drug efflux pump in extensively drug-resistant tuberculosis clinical isolates]. Zhonghua Jie He He Hu Xi Za Zhi 2010
[Novel method for simple detection of mutations conferring drug resistance in Mycobacterium leprae, based on a DNA microarray, and its applicability in developing countries]. doi:10.5025/hansen.79.257 Nihon Hansenbyo Gakkai Zasshi 2010
Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. doi:10.1111/j.1365-2672.2010.04840.x J Appl Microbiol 2010
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. doi:10.1128/AAC.00968-10 Antimicrob Agents Chemother 2010
Emergence and molecular characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates from the Delhi Region in India. doi:10.1128/AAC.00661-10 Antimicrob Agents Chemother 2010
[Molecular characterization of drug-resistant and extensive-drug resistant isolates of Mycobacterium tuberculosis in Shenzhen of China]. Zhonghua Jie He He Hu Xi Za Zhi 2010
Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. doi:10.1093/jac/dkq202 J Antimicrob Chemother 2010
Branched intermediate formation stimulates peptide bond cleavage in protein splicing. doi:10.1038/nchembio.371 Nat Chem Biol 2010
Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China. doi:10.1016/j.jinf.2010.05.001 names it J Infect 2010
Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. doi:10.1128/JCM.01947-09 J Clin Microbiol 2010
Novel multiplex allele-specific PCR assays for the detection of resistance to second-line drugs in Mycobacterium tuberculosis. doi:10.1093/jac/dkq047 J Antimicrob Chemother 2010
Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. doi:10.1093/jac/dkp452 J Antimicrob Chemother 2010
First report of molecular characterization of fluoroquinolone-resistant Mycobacterium tuberculosis isolates from a Tunisian hospital. doi:10.1111/j.1469-0691.2009.03087.x Clin Microbiol Infect 2010
Crystal structure of the DNA gyrase GyrA N-terminal domain from Mycobacterium tuberculosis. doi:10.1002/prot.22600 names it Proteins 2010
Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. doi:10.1128/JCM.01229-09 J Clin Microbiol 2009
Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam. doi:10.1128/AAC.00541-09 Antimicrob Agents Chemother 2009
Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. doi:10.1128/AAC.00287-09 names it Antimicrob Agents Chemother 2009
Epidemiologic characterization of culture positive Mycobacterium tuberculosis patients by katG-gyrA principal genetic grouping. doi:10.2353/jmoldx.2009.080171 names it J Mol Diagn 2009
Semisynthesis of membrane-attached prion proteins. doi:10.1016/S0076-6879(09)62009-7 Methods Enzymol 2009
Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment. doi:10.1128/AAC.00050-09 Antimicrob Agents Chemother 2009
Prevalence of fluoroquinolone resistance among tuberculosis patients in Shanghai, China. doi:10.1128/AAC.00177-09 Antimicrob Agents Chemother 2009
Genotypic rpoB and gyrA profiles for detection of rifampicin and fluoroquinolone susceptibilities of Mycobacterium tuberculosis isolates directly from clinical sputum specimens. doi:10.1016/j.ijantimicag.2009.02.010 names it Int J Antimicrob Agents 2009
Molecular detection of drug-resistant Mycobacterium tuberculosis with a scanning-frame oligonucleotide microarray. doi:10.1007/978-1-59745-207-6_26 Methods Mol Biol 2009
The pentapeptide repeat proteins MfpAMt and QnrB4 exhibit opposite effects on DNA gyrase catalytic reactions and on the ternary gyrase-DNA-quinolone complex. doi:10.1128/JB.01205-08 J Bacteriol 2009
Detection of mutations in Mycobacterium tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological microchips. doi:10.1007/s10517-008-0034-5 Bull Exp Biol Med 2008
A novel method for simple detection of mutations conferring drug resistance in Mycobacterium leprae, based on a DNA microarray, and its applicability in developing countries. doi:10.1099/jmm.0.2008/002600-0 J Med Microbiol 2008
[Drug resistance of multibacillary leprosy patients in Japan--results of molecular genetic analyses]. doi:10.5025/hansen.77.187 Nihon Hansenbyo Gakkai Zasshi 2008
Site-specific chemical modification of proteins with a prelabelled cysteine tag using the artificially split Mxe GyrA intein. doi:10.1002/cbic.200800319 names it Chembiochem 2008
[Rapid detection of mutations in the gyra gene of mycobacterium tuberculosis with relevance for the development of drug resistance against quinolones by real-time PCR on the LightCycler system]. doi:10.1055/s-2008-1038223 names it Pneumologie 2008
Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia. doi:10.1128/AAC.00036-08 Antimicrob Agents Chemother 2008
Fluoroquinolone resistance detection in Mycobacterium tuberculosis with locked nucleic acid probe real-time PCR. Int J Tuberc Lung Dis 2008
Mutagenesis in the alpha3alpha4 GyrA helix and in the Toprim domain of GyrB refines the contribution of Mycobacterium tuberculosis DNA gyrase to intrinsic resistance to quinolones. doi:10.1128/AAC.01380-07 names it Antimicrob Agents Chemother 2008
Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates. doi:10.1016/j.ijantimicag.2007.10.014 names it Int J Antimicrob Agents 2008
Development of multiplex assay for rapid characterization of Mycobacterium tuberculosis. doi:10.1128/JCM.01821-07 J Clin Microbiol 2008
Are all the DNA gyrase mutations found in Mycobacterium leprae clinical strains involved in resistance to fluoroquinolones? doi:10.1128/AAC.01095-07 Antimicrob Agents Chemother 2008
The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Lepr Rev 2007
[Investigation of Mycobacterium tuberculosis sensitivity to fluoroquinolone, by revealing gyrA gene mutations]. names it Probl Tuberk Bolezn Legk 2007
Mycobacterium tuberculosis DNA gyrase as a target for drug discovery. doi:10.2174/187152607781001763 Infect Disord Drug Targets 2007
Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid. doi:10.1159/000109769 Chemotherapy 2007
Drug susceptibility of Spanish Mycobacterium tuberculosis complex isolates from animals. doi:10.1016/j.tube.2007.08.004 Tuberculosis (Edinb) 2007
Polymorphisms in gyrA and gyrB genes among Mycobacterium avium subsp. paratuberculosis type I, II, and III isolates. doi:10.1128/JCM.01411-07 names it J Clin Microbiol 2007
Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. doi:10.1093/jac/dkm061 J Antimicrob Chemother 2007
Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. doi:10.1093/jac/dkm054 J Antimicrob Chemother 2007
Validation of the agar proportion and 2 liquid systems for testing the susceptibility of Mycobacterium tuberculosis to moxifloxacin. doi:10.1016/j.diagmicrobio.2006.08.018 Diagn Microbiol Infect Dis 2007
Limited fluoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national survey. doi:10.1093/jac/dkm038 J Antimicrob Chemother 2007
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. doi:10.1128/AAC.01282-06 Antimicrob Agents Chemother 2007
Association between Mycobacterium tuberculosis Beijing/W lineage strain infection and extrathoracic tuberculosis: Insights from epidemiologic and clinical characterization of the three principal genetic groups of M. tuberculosis clinical isolates. doi:10.1128/JCM.01459-06 J Clin Microbiol 2007
Detection of multidrug resistance in Mycobacterium tuberculosis. doi:10.1128/JCM.00750-06 J Clin Microbiol 2007
A drug-resistant leprosy case detected by DNA sequence analysis from a relapsed Mexican leprosy patient. Rev Latinoam Microbiol 2006
The key DNA-binding residues in the C-terminal domain of Mycobacterium tuberculosis DNA gyrase A subunit (GyrA). doi:10.1093/nar/gkl695 names it Nucleic Acids Res 2006
Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. doi:10.1128/JCM.01916-06 names it J Clin Microbiol 2006
Glutamate racemase from Mycobacterium tuberculosis inhibits DNA gyrase by affecting its DNA-binding. doi:10.1093/nar/gkl704 Nucleic Acids Res 2006
Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. doi:10.1128/AAC.00944-06 Antimicrob Agents Chemother 2006
Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli. doi:10.1093/jac/dkl388 J Antimicrob Chemother 2006
[Study on mutations of gyrA gene of tuberculosis quinolone-tolerant isolates in coal workers' pneumoconiosis]. names it Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2006
Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: functional analysis of mutant enzymes. doi:10.1128/AAC.50.1.104-112.2006 Antimicrob Agents Chemother 2006
Temperature-mediated heteroduplex analysis for the detection of drug-resistant gene mutations in clinical isolates of Mycobacterium tuberculosis by denaturing HPLC, SURVEYOR nuclease. doi:10.1016/j.micinf.2005.06.008 Microbes Infect 2006
Mutations in the gyrA and gyrB genes of fluoroquinolone-resistant Mycobacterium tuberculosis from TB patients in Thailand. names it Southeast Asian J Trop Med Public Health 2005
[Polymerase chain reaction-single strand conformation polymorphism analysis combined with nucleic acid hybridization to detect ofloxacin-resistant Mycobacterium tuberculosis mutation selected in vitro]. Zhonghua Jie He He Hu Xi Za Zhi 2005
Trends in fluoroquinolone resistance of Mycobacterium tuberculosis complex in a Taiwanese medical centre: 1995-2003. doi:10.1093/jac/dki353 J Antimicrob Chemother 2005
Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis. doi:10.1128/AAC.49.7.2928-2933.2005 names it Antimicrob Agents Chemother 2005
A monoclonal antibody that inhibits mycobacterial DNA gyrase by a novel mechanism. doi:10.1093/nar/gki622 Nucleic Acids Res 2005
Validation of the use of Middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin. doi:10.1128/JCM.42.11.5225-5228.2004 J Clin Microbiol 2004
Molecular strain identification of the Mycobacterium tuberculosis complex in archival tissue samples. doi:10.1136/jcp.2003.015719 J Clin Pathol 2004
[Multi-drug resistant Mycobacterium leprae from patients with leprosy]. doi:10.5025/hansen.73.227 Nihon Hansenbyo Gakkai Zasshi 2004
Detection of Mycobacterium tuberculosis genotypic groups by a duplex real-time PCR targeting the katG and gyrA genes. doi:10.1016/j.mimet.2004.06.012 names it J Microbiol Methods 2004
[Molecular identification of mycobacteria and detection of antibiotic resistance]. Ann Biol Clin (Paris) 2004
Genetic polymorphism in Mycobacterium tuberculosis isolates from patients with chronic multidrug-resistant tuberculosis. doi:10.1086/421501 J Infect Dis 2004
[Study on the gene mutation of quinolone-resistant Mycobacterium tuberculosis isolated from Sichuan Province]. Sichuan Da Xue Xue Bao Yi Xue Ban 2004
Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. doi:10.1128/AAC.48.4.1281-1288.2004 Antimicrob Agents Chemother 2004
Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. doi:10.1128/AAC.48.2.596-601.2004 names it Antimicrob Agents Chemother 2004
Mycobacterium tuberculosis isolates belonging to katG gyrA group 2 are associated with clustered cases of tuberculosis in Italian patients. doi:10.1099/jmm.0.05471-0 names it J Med Microbiol 2004
Elevation of Mycobacterium tuberculosis subsp. caprae Aranaz et al. 1999 to species rank as Mycobacterium caprae comb. nov., sp. nov. doi:10.1099/ijs.0.02532-0 Int J Syst Evol Microbiol 2003
Drug susceptibility testing of Mycobacterium tuberculosis to fluoroquinolones: first experience with a quality control panel in the Nordic-Baltic collaboration. Int J Tuberc Lung Dis 2003
Characterization of the Manila family of Mycobacterium tuberculosis. doi:10.1128/JCM.41.6.2723-2726.2003 J Clin Microbiol 2003
Detection of gene mutations related with drug resistance in Mycobacterium leprae from leprosy patients using Touch-Down (TD) PCR. doi:10.1016/S0928-8244(03)00038-5 FEMS Immunol Med Microbiol 2003
Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. doi:10.1128/AAC.47.4.1241-1250.2003 Antimicrob Agents Chemother 2003
Identification of mycobacterial species by PCR sequencing of quinolone resistance-determining regions of DNA gyrase genes. doi:10.1128/JCM.41.3.1311-1315.2003 J Clin Microbiol 2003
Molecular analysis of Mycobacterium tuberculosis DNA from a family of 18th century Hungarians. doi:10.1099/mic.0.25961-0 Microbiology (Reading) 2003
An orphan gyrB in the Mycobacterium smegmatis genome uncovered by comparative genomics. doi:10.1007/BF02715907 J Genet 2002
[The importance of allergic skin test with Johnin, antibody ELISA, cultural fecal test as well as vaccination for the sanitation of three chronically paratuberculosis-infected dairy herds in Rhineland-Palatinate]. Dtsch Tierarztl Wochenschr 2002
Development of a positive genetic selection system for inhibition of protein splicing using mycobacterial inteins in Escherichia coli DNA gyrase subunit A. J Mol Microbiol Biotechnol 2002
Creation of an artificial bifunctional intein by grafting a homing endonuclease into a mini-intein. doi:10.1016/s0022-2836(02)00912-9 J Mol Biol 2002
DNA gyrase genes in Mycobacterium tuberculosis: a single operon driven by multiple promoters. doi:10.1128/JB.184.19.5449-5456.2002 J Bacteriol 2002
Establishment of intein-mediated protein ligation under denaturing conditions: C-terminal labeling of a single-chain antibody for biochip screening. doi:10.1021/bc025534z Bioconjug Chem 2002
Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore. doi:10.1016/s1201-9712(02)90136-0 Int J Infect Dis 2002
Functional characterisation of mycobacterial DNA gyrase: an efficient decatenase. doi:10.1093/nar/30.10.2144 Nucleic Acids Res 2002
Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in North India. doi:10.1128/AAC.46.2.443-450.2002 Antimicrob Agents Chemother 2002
Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. doi:10.1086/324623 Clin Infect Dis 2002
Typing of drug resistant isolates of Mycobacterium tuberculosis from India using the IS6110 element reveals substantive polymorphism. doi:10.1016/s1567-1348(01)00014-4 Infect Genet Evol 2001
Multidrug resistant Mycobacterium leprae from patients with leprosy. doi:10.1128/AAC.45.12.3635-3639.2001 Antimicrob Agents Chemother 2001
Distribution of GyrA intein in non-tuberculous mycobacteria and genomic heterogeneity of Mycobacterium gastri. doi:10.1016/s0014-5793(01)03037-x names it FEBS Lett 2001
Mycobacterium tuberculosis phylogeny reconstruction based on combined numerical analysis with IS1081, IS6110, VNTR, and DR-based spoligotyping suggests the existence of two new phylogeographical clades. doi:10.1007/s002390010255 J Mol Evol 2001
Cleavage and purification of intein fusion proteins using the Streptococcus gordonii spex system. doi:10.1081/PB-100104909 Prep Biochem Biotechnol 2001
Immune reactions in cattle after immunization with a Mycobacterium paratuberculosis vaccine and implications for the diagnosis of M. paratuberculosis and M. bovis infections. doi:10.1046/j.1439-0450.2001.00443.x J Vet Med B Infect Dis Vet Public Health 2001
Monoclonal antibodies to mycobacterial DNA gyrase A inhibit DNA supercoiling activity. doi:10.1046/j.1432-1327.2001.02077.x Eur J Biochem 2001
Inhibitory activity of quinolones against DNA gyrase of Mycobacterium tuberculosis. doi:10.1093/jac/47.4.447 J Antimicrob Chemother 2001
Transmission dynamics and molecular characterization of Mycobacterium tuberculosis isolates with low copy numbers of IS6110. doi:10.1128/JCM.39.1.217-221.2001 J Clin Microbiol 2001
Genetic diversity and evidence for acquired antimicrobial resistance in Mycobacterium tuberculosis at a large hospital in South India. doi:10.1016/s1201-9712(00)90075-4 Int J Infect Dis 2000
Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations. doi:10.1086/315708 J Infect Dis 2000
Characterization of Mycobacterium tuberculosis isolates from patients in Houston, Texas, by spoligotyping. doi:10.1128/JCM.38.2.669-676.2000 J Clin Microbiol 2000
Molecular characterization of mycobacteria isolated from seals. doi:10.1099/00221287-145-9-2519 Microbiology (Reading) 1999
Mycobacterium tuberculosis subsp. caprae subsp. nov.: a taxonomic study of a new member of the Mycobacterium tuberculosis complex isolated from goats in Spain. doi:10.1099/00207713-49-3-1263 Int J Syst Bacteriol 1999
The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins. doi:10.1074/jbc.274.26.18359 J Biol Chem 1999
Molecular epidemiologic evaluation of transmissibility and virulence of Mycobacterium tuberculosis. doi:10.1128/JCM.37.6.1764-1770.1999 J Clin Microbiol 1999
In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. doi:10.1128/AAC.43.5.1077 Antimicrob Agents Chemother 1999
Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. doi:10.1128/AAC.43.3.661 Antimicrob Agents Chemother 1999
Genotypic characterization of drug-resistant Mycobacterium tuberculosis isolates from Peru. doi:10.1054/tuld.1998.0013 Tuber Lung Dis 1998
[Mechanisms of drug-resistance in mycobacteria]. Nihon Rinsho 1998
[Multidrug-resistant tuberculosis. 2. Mechanisms of drug-resistance in Mycobacterium tuberculosis--genetic mechanisms of drug-resistance]. Kekkaku 1998
Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. doi:10.1128/AAC.42.11.2978 Antimicrob Agents Chemother 1998
Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. doi:10.1128/AAC.42.8.2084 Antimicrob Agents Chemother 1998
Inteins in mycobacterial GyrA are a taxonomic character. doi:10.1099/00221287-144-2-589 names it Microbiology (Reading) 1998
Crystal structure of GyrA intein from Mycobacterium xenopi reveals structural basis of protein splicing. doi:10.1038/nsb0198-31 names it Nat Struct Biol 1998
Molecular techniques in the diagnosis of drug-resistant tuberculosis. Ann Acad Med Singap 1997
[Rapid diagnosis of tuberculosis]. Kekkaku 1997
Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team. doi:10.1097/00002030-199712000-00011 AIDS 1997
The Mycobacterium xenopi GyrA protein splicing element: characterization of a minimal intein. doi:10.1128/jb.179.20.6378-6382.1997 names it J Bacteriol 1997
Nonradioactive single-strand conformation polymorphism analysis for detection of fluoroquinolone resistance in mycobacteria. doi:10.1007/BF01726372 Eur J Clin Microbiol Infect Dis 1997
Gene arrangement and organization in a approximately 76 kb fragment encompassing the oriC region of the chromosome of Mycobacterium leprae. doi:10.1099/13500872-142-11-3147 Microbiology (Reading) 1996
Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. doi:10.1093/infdis/174.5.1127 J Infect Dis 1996
Sequence analysis, purification, and study of inhibition by 4-quinolones of the DNA gyrase from Mycobacterium smegmatis. doi:10.1128/AAC.40.9.2054 Antimicrob Agents Chemother 1996
Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. doi:10.1128/AAC.40.8.1768 Antimicrob Agents Chemother 1996
gyrA of ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong. doi:10.1093/jac/37.5.1032 names it J Antimicrob Chemother 1996
Homing events in the gyrA gene of some mycobacteria. doi:10.1073/pnas.93.8.3410 names it Proc Natl Acad Sci U S A 1996
Organization of the origins of replication of the chromosomes of Mycobacterium smegmatis, Mycobacterium leprae and Mycobacterium tuberculosis and isolation of a functional origin from M. smegmatis. doi:10.1111/j.1365-2958.1996.tb02617.x Mol Microbiol 1996
Mycobacterium smegmatis DNA gyrase: cloning and overexpression in Escherichia coli. doi:10.1099/13500872-141-12-3029 Microbiology (Reading) 1995
Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. doi:10.2165/00003495-199500492-00006 Drugs 1995
Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. names it J Infect Dis 1994
Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones. doi:10.1128/AAC.38.9.1991 Antimicrob Agents Chemother 1994
Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. doi:10.1093/infdis/170.2.479 names it J Infect Dis 1994
Molecular cloning of gyrA and gyrB genes of Mycobacterium tuberculosis: analysis of nucleotide sequence. names it Biochem Mol Biol Int 1994
Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. doi:10.1128/AAC.38.4.773 names it Antimicrob Agents Chemother 1994
Amplification and nucleotide sequence of the quinolone resistance-determining region in the gyrA gene of mycobacteria. doi:10.1111/j.1574-6968.1994.tb06674.x names it FEMS Microbiol Lett 1994
A PCR method for the sequence analysis of the gyrA, polA and rnhA gene segments from mycobacteria. doi:10.1016/0378-1119(93)90481-h names it Gene 1993
Characterization of Escherichia coli men mutants defective in conversion of o-succinylbenzoate to 1,4-dihydroxy-2-naphthoate. doi:10.1128/jb.152.3.1132-1137.1982 J Bacteriol 1982

Title+abstract index only: a paper that names this gene solely in its body text, a figure legend or a supplement is invisible here. That is why this list sits beside the curated layer rather than replacing it - Rv0007's characterisation, found by a full-text sweep, returns zero in this one. Absence from this list is not absence from the literature. Source: PubMed E-utilities sweep (esearch + esummary), every alias of the gene searched in conjunction with a mycobacterial context term; ambiguous common-word aliases excluded. phase198, 2026-09-06.

This layer CITES the literature and adds context; it does not change the verdict or the function stated elsewhere in this fiche. This distinguishes a gene that is dark because nobody has looked from one that is dark despite having been studied. Source: PubMed (whole): H37Rv locus tag + GENE NAME + ortholog identifiers (Mb…, MMAR_…, MSMEG_…, ML…, MAB_…), under a mycobacterial context filter; hits verified against the abstract text. Species-context counts distinguish M. tuberculosis literature from literature on other mycobacteria. phase76/phase77, 2026-07-13.

Post-translational modifications

1 reported modified residue(s): N-acetylthreonine @2.

Experimentally reported post-translational modification(s). A phosphosite indicates the protein is expressed and is a substrate of the M. tuberculosis Ser/Thr/Tyr kinase signalling network — a regulatory context, NOT a molecular function. Source: UniProt (Modified residue features; PTM sites curated from the M. tuberculosis literature).

CRISPRi vulnerability

Vulnerability index -9.08 (95% CI -10.27 to -7.93). A more negative index = more vulnerable to knockdown (better drug-target quality); indicative threshold VI ≤ -6 = highly vulnerable.

Quantitative CRISPRi knockdown, graded (finer than binary Tn-seq essentiality). Source: CRISPRi vulnerability index (Bosch 2021, supplementary Table S2 'mmc3.xlsx', bulk import via Europe PMC -- supersedes the per-gene pebble.rockefeller.edu scrape of phase46_crispri_vulnerability.py).

Legacy record & comparison (Mycobrowser)

Mycobrowser functionDNA gyrase negatively supercoils closed circular double-stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings [catalytic activity: ATP-dependent breakage, passage and rejoining of double-stranded DNA].
Mycobrowser EC 5.99.1.3 · agrees with the atlas

The legacy Mycobrowser record is shown for verification. Mycobrowser is no longer maintained; its EC numbers predate recent nomenclature revisions, so a class change usually reflects re-numbering, not a conflict.

Orthologues (reciprocal best hits across mycobacteria)

M. bovis Mb0006 · 99.5% identity
M. leprae ML0006 · 60.6% identity
M. marinum MMAR_0006 · 92.6% identity
M. smegmatis MSMEG_0006 · 91.4% identity
M. orygis RJtmp_000006 · 99.6% identity
M. abscessus MAB_0019 · 89.7% identity

Reciprocal-best-hit orthologues (DIAMOND) against the Mycobrowser reference proteomes. A missing species is informative: e.g. a gene absent from M. leprae was likely lost in its reductive genome evolution. Locus tags link to Mycobrowser.

Curated reference (UniProt)

UniProt P9WG47 SwissProt · reviewed · Evidence at protein level
UniProt nameDNA gyrase subunit A
EC (curated) EC 5.6.2.2
Curated functionA type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to maintain chromosomes in an underwound state, while in the absence of ATP it relaxes supercoiled dsDNA. Also catalyzes the interconversion of other topological isomers of dsDNA rings, including catenanes. Gyrase from M.tuberculosis has higher decatenation than supercoiling activity compared to E.coli; as M.tuberculosis only has 1 type II topoisomerase, gyrase has to fulfill the decatenation function of topoisomerase IV as well. At comparable concentrations M.tuberculosis gyr.

Functional vocabulary (eggNOG-mapper, orthology transfer)

COG category L Replication, recombination and repair
Preferred namegyrA
eggNOG descriptionA type II topoisomerase that negatively supercoils closed circular double-stranded (ds) DNA in an ATP-dependent manner to modulate DNA topology and maintain chromosomes in an underwound state. Negative supercoiling favors strand separation, and DNA replication, transcription, recombination and repair, all of which involve strand separation. Also able to catalyze the interconversion of other topological isomers of dsDNA rings, including catenanes and knotted rings. Type II topoisomerases break and join 2 DNA strands simultaneously in an ATP-dependent manner
Orthologous groupCOG0188
EC number EC 5.99.1.3
KEGG orthology K02469
Gene Ontology (66) GO:0000166, GO:0000287, GO:0003674, GO:0003824, GO:0003916, GO:0003918, GO:0005488, GO:0005524, GO:0005575, GO:0005618, GO:0005623, GO:0005886 +54 more

Orthology-based transfer (eggNOG 5.0.2, diamond). EC/KO/GO/CAZy are computed annotations, not manual curation; cross-check against the primary literature before treating a specific reaction as established.

Conservation & selection (intra-MTBC, 142 601 strains, snapshot of 2026-09-29)

pN/pS 0.466 · purifying
Polymorphic sites (≥ 0.1% of strains) 16 synonymous, 22 missense, 0 nonsense, 0 frameshift

pN/pS from segregating SNPs (singletons removed) normalised by possible sites. Low pN/pS = purifying selection (a strong signal that a "hypothetical" is a real, constrained gene). A high pN/pS is ambiguous: relaxed constraint or positive selection (drug resistance, antigenic variation) inflate it; e.g. rpoB/katG/pncA score high here for resistance, not loss of function. A clonal disruption (one allele over a clade) suggests lineage pseudogenisation; a convergent one (many independent alleles) is typical of resistance loss-of-function.

Outgroup conservation (beyond the MTBC) Bacteria

M. canettii dN/dS (deep-divergence selection) 0.062 · 26 consensus substitution(s)
under purifying selection vs M. canettii (deep divergence; dN/dS=0.062) — a real, constrained gene predating the MTBC clonal expansion
Limitation: dN/dS mixes fixed canettii-H37Rv divergence with intra-canettii polymorphism, and is not polarised (the per-gene repolarisation is not viable: 79 % of the consensus SPDI lie outside the polarised table).
Genus-wide presence (~53 non-MTBC Mycobacterium) present in 53/53 (100%) · mean identity 94.5% · 4/4 closest MTBAP relatives
conserved across the genus (present in 53/53 non-MTBC Mycobacterium genomes, incl. distant relatives) — an ancient core gene predating the genus radiation
Phylostratum (deepest detected homolog) MTBC-specific → Mycobacterium → Mycobacteriaceae → Corynebacteriales → Actinomycetia → Bacteria
detected in 13/13 non-Mycobacterium reference genomes (down to Bacteria) · mean identity 70.9%
detected down to outside the phylum (Proteobacteria/Firmicutes controls) — a universally conserved, ancient bacterial gene

Two orthogonal outgroup signals. M. canettii (the immediate outgroup) gives a deep-divergence dN/dS (a low value confirms a constrained, real gene; shown as confident only at ≥8 substitutions, else flagged low-power). Genus-wide presence/absence (tblastn vs assembled non-MTBC genomes) places the gene on the ancient-core ↔ MTBC-specific axis: a gene absent even from the closest MTBAP relatives is a candidate MTBC-specific innovation (possible host-adaptation factor, to confirm by synteny). The phylostratum extends that axis outside the genus (tblastn vs 13 reference genomes spanning Mycobacteriaceae → Corynebacteriales → Actinomycetia → outside the phylum): it is the deepest clade in which a homolog is still detected, i.e. a proxy for gene age. Read it with the null model in mind: a shallow (young) stratum can also reflect homology-detection failure for short or fast-evolving ORFs, so it is a descriptive axis, not a proof of novelty.

Essentiality (transposon mutagenesis) essential

DeJesus 2017 callES · essential
What the call meansessential: insertions absent across the whole ORF
TA sites (Himar1) 46 in the ORF — 44 in the essential state, 0 growth-defect, 2 non-essential, 0 growth-advantage. Saturation 0.130, mean read count 21.6666666667. A region of the protein devoid of TA sites is invisible to this assay: nothing can be inferred about it, in either direction.
All 46 sites lie in this ORF alone (no overlapping CDS shares any), so the call is attributable to this gene.

Genome-wide Himar1 transposon essentiality in H37Rv (DeJesus 2017). An essential call (ES/ESD/GD) is strong, independent evidence that a "hypothetical" locus encodes a functional, selectively required gene — orthogonal to intra-species conservation.

Chemical-genetic target & druggability (PROSPECT) hypomorph tool strain

This gene is part of the PROSPECT collection of TetON transcriptional-knockdown (hypomorph) strains of essential M. tuberculosis genes, built as a sensitised background for chemical-genetic mechanism-of-action deconvolution. Being in the panel means the gene is an essential / vulnerable target for which a validated knockdown tool strain exists.

Hypomorph straingyrA-FLAG-tetOn-10 (TetON promoter 10)
Baseline knockdown fitness4.57 median doublings (across 6 screen pool(s)) — fewer doublings = stronger growth defect on knockdown
Used in target deconvolutionyes (informs phenotypic-cluster / MOA assignment)

Panel membership reflects essentiality/vulnerability and the availability of a genetic tool, not a specific molecular function; it never changes the verdict here. Source: Bond AN et al., Nat Commun 2025;16:9673 (doi:10.1038/s41467-025-64662-x); PROSPECT chemical-genetic platform.

Mutant phenotypes (conditional Tn-seq, MtbTnDB)

Conditionlog2FCqEffect
differential fitness in a comparison whose nature could not be established (upstream metadata defect, see note) (undetermined) -2.400.012 required

Conditional fitness of transposon-disruption mutants across 1 significant condition(s) (|log2FC|≥1, q≤0.05), from the standardized MtbTnDB compendium. A negative log2FC means the mutant is depleted — the gene contributes to fitness in that condition. An in-vivo defect for a "hypothetical" is strong evidence it matters for infection, even without a known molecular function. Disruption (Tn insertion), not a clean deletion; genetic-interaction screens excluded.

Provenance note on a condition above. MtbTnDB labels this condition in vivo (Collaborative Cross mouse panel) and attributes it to Smith et al. 2022, eLife 74419. Both are wrong and for the same reason: its left arm, `mbio_H37Rv`, is the saturated H37Rv reference of DeJesus et al. 2017 (mBio 8(1):e02133-16, fourteen independent Tn libraries grown in standard medium), not a mouse strain, and the upstream generator read the token before `_vs_` as a mouse-strain name. The same sample is the in vitro control of six knockout screens in the same file. Measured here on rank correlation over 3971 genes: this condition tracks the other 81 first-order in vivo conditions at rho = +0.03, where those conditions track each other at +0.270 -- it does not behave like an infection measurement. What the comparison actually is could not be established, so it is reported as undetermined rather than renamed, and it is excluded from the in vivo count of this fiche.

Drug resistance (WHO catalogue) levofloxacinmoxifloxacin

levofloxacin19 catalogued resistance-associated variant(s)
moxifloxacin19 catalogued resistance-associated variant(s)

This gene carries mutations classed Associated with resistance (WHO grade 1–2) in the consolidated catalogue (WHO 2nd ed. 2023 + tb-profiler). Only the R-associated tier is shown; "uncertain" and empirical-only signals are excluded. Test a specific strain or variant with the resistance tester. Research context, not a clinical diagnostic.

Proteomics (mass spectrometry) detected

MS detectiondetected in 15 of 16 independent MS datasets
Integrated abundance448.0 ppm · rank 447/3519 (87.3th percentile)

Detection by mass spectrometry is direct, experimental evidence that the protein product exists — orthogonal to sequence conservation and to Tn-seq essentiality, and especially decisive for a "hypothetical" locus. Read the dataset count as abundance, not as replication. Measured across this atlas (3,491 detected proteins), the number of datasets a protein appears in tracks its abundance almost monotonically: median 1.2 ppm at 1 dataset of 16, 27 ppm at 10, 392 ppm at 15, 1,325 ppm at 16 — three orders of magnitude. A high count therefore says the protein is abundant more than it says several independent experiments confirmed it. What the count does establish, at any value, is that the product exists.

Predicted localisation (DeepTMHMM + lipobox) no export signal, no TM helix

Predictionno signal peptide, no TM helix (DeepTMHMM class GLOB)
DeepTMHMM classGLOB

A verified absence of signals, which is not a compartment. No Sec/Tat signal peptide, no transmembrane helix and no lipobox were found on this sequence. The predictor reports topology and export signals; it does not measure where the protein ends up, so this page draws no cytoplasmic conclusion from it. In M. tuberculosis that reservation is not theoretical: the 12 Esx paralogues of this atlas — EsxA/ESAT-6 and EsxB/CFP-10 among them, the best-established secreted proteins of the species — carry this very call, because substrates of the type VII (ESX) secretion system leave no recognisable signal. « Secreted » and « no signal peptide » are true together here.

Transmembrane topology and signal peptide from DeepTMHMM (deep-learning reference predictor); lipoproteins from a (myco)bacterial lipobox motif. A sequence-based prediction of subcellular context.

Physico-chemical properties (computed, ProtParam)

Length838 aa
Molecular weight92.3 kDa
Theoretical pI5.41
GRAVY-0.306 (hydrophilic)
Aliphatic index95.7
Aromaticity0.053
Instability index37.1 (stable)

Computed from the ancestral MTBC0 sequence with the ExPASy ProtParam method (Biopython). Descriptive biophysical context: a positive GRAVY flags a hydrophobic (often membrane) protein, a high instability index (>40) predicts a short in-vitro half-life, an extreme pI hints at compartment or binding partner.

Domains (Pfam, hmmscan --cut_ga)

PfamAccessioni-EvalueResiduesDescription
DNA_topoisoIVPF00521.27 3.6e-15239–483 DNA gyrase/topoisomerase IV, subunit A
DNA_gyraseA_CPF03989.19 1.3e-12515–562 DNA gyrase C-terminal domain, beta-propeller

3D structure (interactive — Mol*/pdbe-molstar)

Experimental structure 8s7o (PDBe), the strongest available structural evidence for this gene. Drag to rotate, scroll to zoom; hetero-groups (ligands, ions, waters hidden by default) shown as sticks.

Experimental structures (Protein Data Bank) 19 solved

PDBMethodResolutionCoverage
8s7o Electron Microscopy 2.8 Å 100%
8s7k Electron Microscopy 3.2 Å 100%
6gav X-ray diffraction 2.6 Å 60%
3ifz X-ray diffraction 2.7 Å 60%
7ugw X-ray diffraction 3.0 Å 60%
6gau X-ray diffraction 3.3 Å 60%
5bs8 X-ray diffraction 2.399 Å 59%
5btd X-ray diffraction 2.497 Å 59%

Experimentally solved structures mapped from the UniProt accession via PDBe/SIFTS (19 total; up to 8 shown, ranked by sequence coverage then resolution). An experimental structure is direct proof of the folded product and the strongest structural evidence — superseding the predicted ESMFold/AlphaFold models below for any covered region.

Structural search (AlphaFold DB model, Foldseek vs PDB — genome-wide) pLDDT 88.9

PDB hitprobTM (aln)TM (query)TM (target)Seq. id.Cov. q / tE-valueDescription
5bs8-assembly1_A 1.00 0.98 0.57 0.98 100% 58% / 100% 4.6e-79 sig 5bs8-assembly1_A Crystal structure of a topoisomerase II complex
5btf-assembly1_A 1.00 0.98 0.57 0.98 100% 58% / 100% 5.6e-79 sig 5btf-assembly1_A Crystal structure of a topoisomerase II complex
9foy-assembly1_A 1.00 0.98 0.57 0.66 100% 58% / 66% 2.9e-78 sig 9foy-assembly1_A Ternary complex of a Mycobacterium tuberculosis DNA gyrase core fusion with DNA and the inhibitor AMK32b
7ugw-assembly1_C 1.00 0.98 0.57 0.98 100% 58% / 100% 7.7e-77 sig 7ugw-assembly1_C M. tuberculosis DNA gyrase cleavage core bound to DNA and evybactin
7ugw-assembly1_A 1.00 0.98 0.57 0.98 99% 58% / 100% 1.4e-76 sig 7ugw-assembly1_A M. tuberculosis DNA gyrase cleavage core bound to DNA and evybactin

Foldseek search of the AlphaFold DB model (mean pLDDT 88.9, gated at 70) against the PDB — a genome-wide extension of the ESMFold dark-gene search that also covers proteins beyond the single-sequence length limit. Confident structural neighbours (E < 0.01) shown.

Genomic context (neighbours & predicted operon) operon of 2

Upstream (5' on genome)gyrB (+ strand, 34 bp gap)
Downstream (3' on genome)Rv0007 (+ strand, 95 bp gap)
Predicted operon gyrB · gyrA

Neighbours from the H37Rv annotation (+ strand). The operon is predicted by co-directional intergenic distance (same strand, gaps ≤50 bp) — a transcription-unit hypothesis, not a mapped TSS. For a "hypothetical", co-transcription with a characterised operon is a concrete functional lead (complements the STRING neighborhood channel below).

Published operon evidence (two independent sources)

Roback 2007 (logistic regression: distance + expression correlation, 474 microarrays) operon of 3: gyrB · gyrA · Rv0007 — disagrees with the distance heuristic above
REMap 2016 (RNA-seq coverage continuity, CDC1551, tag MT0006) exponential phase: operon of 6, Rv0002 · Rv0003 · Rv0004 · Rv0005 · Rv0006 · Rv0007 (coverage 100.91)
stationary phase: operon of 2, Rv0005 · Rv0006 (coverage 40.86) — agrees with the distance heuristic above

Two independent published operon maps, cited alongside the distance heuristic above: an association corroborating or contradicting the heuristic, never proof of shared function. REMap's RNA-seq coverage continuity is the most direct of the three signals; Roback's logistic regression and the intergenic-distance heuristic are statistical proxies.

Transcriptional regulation (signed TRN: ChIP-seq + TFOE)

Regulated by (1 TF) Rv0023 (represses)

Regulatory edges from the ISB signed transcriptional regulatory network (TF ChIP-seq binding, Minch 2015 + TF-overexpression response, Rustad 2014). An edge is regulatory evidence (binding and/or expression change), not necessarily direct. For a "hypothetical", membership in a known regulon (e.g. DosR dormancy, PhoP virulence) is a physiological-context lead, not a function.

Condition: Condition-blind by construction. These edges come from transcription-factor OVEREXPRESSION in a single laboratory condition, so a listed regulator is not a claim that it governs this gene in every circumstance. Measured counter-examples exist within this atlas (see Rv2516c, where the DosR regulon collapses under moxifloxacin while the gene itself rises). Read a regulator as 'capable of shifting this gene', and look for the condition before building a hypothesis on it.

Additional regulons (curated, outside the TFOE-derived TRN)

crp binding site only -- direction not determined (low confidence · CRP regulon (Kahramanoglou et al. 2014))
ChIP-seq : site de fixation CRP (1 des 191 sites de Kahramanoglou et al. 2014) ; aucun changement d'expression rapporte pour ce gene chez le mutant delta-crp
Caveat: Site de fixation CRP mesure par ChIP-seq (Kahramanoglou et al. 2014), SANS changement d'expression mesure pour ce gene chez le mutant delta-crp : le sens de la regulation n'est PAS determine. Ecrire « site de fixation CRP en amont », jamais « regule par CRP ». L'article ne distingue pas « non differentiellement exprime » de « sous le seuil », donc l'absence de ce gene de la table d'expression n'est pas une preuve de non-regulation.

Curated from primary literature not covered by the ISB signed TRN (Minch 2015 / Rustad 2014): Zur regulon (Maciag et al. 2007, PMID 17098899), SigG regulon (Gaudion et al. 2013, PMID 23871545), LexA/SOS regulon (Smollett et al. 2012, PMID 22528497) — added P16.25 (2026-08-18); CRP regulon (Kahramanoglou et al. 2014, PMID 24957601) — added P16.25b (2026-09-27). Confidence and caveats are per-edge and carried from the source paper — read them before citing a specific gene as "regulated by" its listed TF. An entry reading "binding site only — direction not determined" is not a regulation claim: it records a measured ChIP-seq binding site for which the source reports no expression change, and the absence of such a change is not evidence of absent regulation.

Functional interaction network (STRING v12, guilt-by-association)

Explore full network →

Node colour = verdict, dashed = still uncharacterised; edge colour = evidence (green experimental, orange genomic-context, grey co-expression), width ∝ score. Click a partner to open its page; "Explore full network" to walk the graph.

Closest characterised functional partner: gyrB (DNA gyrase subunit B), high confidence (score 1000, all STRING channels except text-mining; the partner is chosen on its genomic-context evidence). The pair rests on an interaction measured in M. tuberculosis itself (own experimental score 900): a measured association in this organism, as opposed to one carried over from other proteomes.

Showing the 15 strongest of this gene's 157 partners at medium confidence (39 at high confidence). The table is an extract, not a neighbourhood: across the proteome the real median degree is 34 while the served median is 15, so no hub, degree distribution or centrality may be read on this table. Of the 157 partners, 1 rest on an interaction measured in M. tuberculosis itself.

PartnerProductScoreNo text-miningChannels (≥400)
Rv0005 gyrB measured in Mtb DNA gyrase subunit B 999 1000 ctx neighborhood:830 cooccurence:773 coexpression:942 experimental:981 textmining:989
Rv0007 membrane protein 946 943 ctx neighborhood:775 coexpression:757
Rv1797 eccE5 ESX-5 type VII secretion system protein EccE 746 746 coexpression:746
Rv3806c ubiA decaprenyl-phosphate phosphoribosyltransferase 784 738 coexpression:730
Rv1307 atpH ATP synthase subunit b/delta 682 682 coexpression:658
Rv0640 rplK 50S ribosomal protein L11 713 676 coexpression:589
Rv0641 rplA 50S ribosomal protein L1 655 617 coexpression:538
Rv0002 dnaN DNA polymerase III subunit beta 887 615 ctx neighborhood:604 textmining:719
Rv2373c dnaJ2 chaperone protein DnaJ 720 614 ctx cooccurence:599
Rv0350 dnaK chaperone protein DnaK 747 609 ctx cooccurence:513
Rv2150c ftsZ cell division protein FtsZ 870 597 textmining:692
Rv1650 pheT phenylalanine--tRNA ligase subunit beta 675 575 coexpression:430
Rv0705 rpsS 30S ribosomal protein S19 595 575 coexpression:415
Rv0667 rpoB DNA-directed RNA polymerase subunit beta 980 549 coexpression:455 textmining:959
Rv0003 recF DNA replication/repair protein RecF 861 548 ctx neighborhood:525 textmining:707

STRING combines evidence channels (neighborhood, fusion, cooccurrence, coexpression, experimental, database, text-mining) into a 0–1000 score. The ctx badge marks edges carried by the genomic-context channels (conserved neighborhood, fusion, phylogenetic co-occurrence), which are independent of orthology and structure and the strongest signal for an unknown gene. The no text-mining column recomputes the score from data alone, so a link that does not depend on the literature is visible. Association is a function hypothesis, not proof: corroborate with the operon context and the primary literature before assigning a function.

Where the experimental evidence comes from, and why it matters here. STRING's experimental channel fuses interactions measured in M. tuberculosis with interactions measured in another organism and transferred to this pair by orthology. The two are not equivalent for this atlas, whose standing rule is that better studied elsewhere is not a function established in M. tuberculosis. Measured on the served network: of the 38 229 partner pairs shown across the atlas, 13 483 partner rows carry a non-zero experimental channel, and only 106 pairs rest on an interaction measured in M. tuberculosis itself — 0.3 % of the network. Those 106 are long-established complexes (ESX-1/ESAT-6, RNA polymerase with CarD and RbpA, the Pup–Mpa proteasome, gyrase, Emb, GarA with PknB and PknG, the Rel modules); no still-uncharacterised gene is among them. The reason is not a gap in this atlas but in the literature: there is almost no experimental interactome of this bacterium, IntAct holding 134 curated protein pairs for a ~4 000-gene proteome. A exp (transferred) badge is therefore a lead, never a measurement, and an absence of badge is not evidence that the pair does not interact.

Evidence

  • Legacy H37Rv annotation: DNA gyrase subunit A
  • MTBC0 PGAP product: DNA topoisomerase (ATP-hydrolyzing) subunit A
  • Pfam (hmmscan --cut_ga): DNA_topoisoIV PF00521.27 (E=4e-152), DNA_gyraseA_C PF03989.19 (E=1e-12)
  • (auto-curated by rules from PGAP + Pfam + Foldseek; not hand-reviewed)

Sources

  • Ancestral sequence & coordinates: Harrison LB et al. (2024), An imputed ancestral reference genome for the MTBC, doi:10.1101/2023.09.07.556366
  • Product annotation: NCBI PGAP on MTBC0; legacy from H37Rv NC_000962.3 (RefSeq NP_214520.1)
  • Domains: Pfam-A via hmmscan --cut_ga — DNA_topoisoIV (PF00521.27), DNA_gyraseA_C (PF03989.19)
  • Sequence-level signal: ESM Atlas (EvolutionaryScale × BioHub) — exploratory
  • Controlled vocabulary: eggNOG-mapper 2.1.12 (Cantalapiedra et al. 2021, doi:10.1093/molbev/msab293), eggNOG 5.0 DB (Huerta-Cepas et al. 2019) — OG COG0188
  • Curated reference: UniProt P9WG47 (SwissProt, reviewed; Evidence at protein level)
  • Intra-MTBC selection: pN/pS and disruption from SPDI variants of 142 601 MTBC strains (this work, local collection vs H37Rv NC_000962.3)
  • Genome-wide structure: AlphaFold DB model (Jumper et al. 2021, doi:10.1038/s41586-021-03819-2; Varadi et al. 2024, doi:10.1093/nar/gkad1011) searched vs PDB with Foldseek (mean pLDDT 88.9)
  • Interaction network: STRING v12.0 (Szklarczyk et al. 2023, doi:10.1093/nar/gkac1000), taxon 83332, CC-BY 4.0 — 157 functional partner(s); context anchor gyrB
  • Essentiality: genome-wide transposon mutagenesis in H37Rv — DeJesus et al. 2017 (mBio, doi:10.1128/mBio.02133-16, CC BY)
  • Proteomics: integrated mass-spectrometry abundance from PaxDb 5.0 (Huang et al. 2023, doi:10.1016/j.mcpro.2023.100640), taxon 83332 — weighted average of 16 datasets, incl. Schubert et al. 2013 (doi:10.1016/j.chom.2013.04.008) and Albrethsen et al. 2013 (doi:10.1074/mcp.M112.018846)
  • Functional category: TubercuList scheme (Cole et al. 1998, doi:10.1038/31159), via Mycobrowser (Kapopoulou et al. 2011, doi:10.1016/j.tube.2010.09.006)
  • Orthologues: reciprocal best hits (DIAMOND, Buchfink et al. 2021, doi:10.1038/s41592-021-01101-x) against Mycobrowser release 5 reference proteomes
  • Experimental structures: PDBe/SIFTS UniProt→PDB mapping (Dana et al. 2019, doi:10.1093/nar/gky1114)
  • Genomic context / operon: H37Rv annotation; operon predicted by co-directional intergenic distance (Salgado et al. 2000, doi:10.1073/pnas.030539397)
  • Transcriptional regulation: ISB signed TRN — TF ChIP-seq (Minch et al. 2015, doi:10.1038/ncomms6829) + TF overexpression (Rustad et al. 2014, doi:10.1186/gb-2014-15-11-502)
  • Mutant phenotypes: standardized Tn-seq compendium MtbTnDB (Jinich et al. 2025, doi:10.1111/mmi.15370), aggregating many primary Tn-seq studies across conditions
  • Drug resistance: consolidated catalogue, WHO 2nd ed. 2023 (9789240082410) + tb-profiler; only the resistance-associated tier (grade 1–2) is surfaced
  • Physico-chemical properties: ExPASy ProtParam method via Biopython (Gasteiger et al. 2005), computed from the MTBC0 sequence
  • Predicted localisation: DeepTMHMM (Hallgren et al. 2022, doi:10.1101/2022.04.08.487609) for transmembrane topology and signal peptide
  • Primary literature: none located yet; annotation rests on the domain/homology sources above.

Ancestral MTBC0 protein sequence

>mtbc0_000006|Rv0006|gyrA
MTDTTLPPDDSLDRIEPVDIQQEMQRSYIDYAMSVIVGRALPEVRDGLKPVHRRVLYAMFDSGFRPDRSHAKSARSVAETMGNYHPHGDASIYDTLVRMAQPWSLRYPLVDGQGNFGSPGNDPPAAMRYTEARLTPLAMEMLREIDEETVDFIPNYDGRVQEPTVLPSRFPNLLANGSGGIAVGMATNIPPHNLRELADAVFWALENHDADEEETLAAVMGRVKGPDFPTAGLIVGSQGTADAYKTGRGSIRMRGVVEVEEDSRGRTSLVITELPYQVNHDNFITSIAEQVRDGKLAGISNIEDQSSDRVGLRIVIEIKRDAVAKVVINNLYKHTQLQTSFGANMLAIVDGVPRTLRLDQLIRYYVDHQLDVIVRRTTYRLRKANERAHILRGLVKALDALDEVIALIRASETVDIARAGLIELLDIDEIQAQAILDMQLRRLAALERQRIIDDLAKIEAEIADLEDILAKPERQRGIVRDELAEIVDRHGDDRRTRIIAADGDVSDEDLIAREDVVVTITETGYAKRTKTDLYRSQKRGGKGVQGAGLKQDDIVAHFFVCSTHDLILFFTTQGRVYRAKAYDLPEASRTARGQHVANLLAFQPEERIAQVIQIRGYTDAPYLVLATRNGLVKKSKLTDFDSNRSGGIVAVNLRDNDELVGAVLCSADDDLLLVSANGQSIRFSATDEALRPMGRATSGVQGMRFNIDDRLLSLNVVREGTYLLVATSGGYAKRTAIEEYPVQGRGGKGVLTVMYDRRRGRLVGALIVDDDSELYAVTSGGGVIRTAARQVRKAGRQTKGVRLMNLGEGDTLLAIARNAEESGDDNAVDANGADQTGN